

OPIC
OFFICE DE LA PROPRIÉTÉ
INTELLECTUELLE DU CANADA



CIPO
CANADIAN INTELLECTUAL
PROPERTY OFFICE

Ottawa Hull K1A 0C9

(21) (A1) 2,144,475
(22) 1995/03/13
(43) 1995/09/15

(51) Int.Cl. ⁶ C12Q 1/68; C12Q 1/70; C07K 9/00; C07H 21/00; A61K
38/14; A61K 31/70

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Polyamide-Oligonucleotide Derivatives, Their Preparation
and Use

(72) Uhlmann, Eugen - Germany (Federal Republic of) ;
Breipohl, Gerhard - Germany (Federal Republic of) ;

(71) Hoechst Aktiengesellschaft - Germany (Federal Republic
of) ;

(30) (DE) P 44 08 528.1 1994/03/14

(57) 15 Claims

Notice: This application is as filed and may therefore contain an
incomplete specification.



Industrie Canada Industry Canada

Canada


2144475

HOE 94/F 057

Abstract of th disclosure

Polyamide-oligonucleotide derivatives, their preparation and use

Polyamide-oligonucleotide derivatives of the formula



wherein q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t ≥ 2 ; x is 1 to 20; DNA is a nucleic acid such as DNA or RNA or a known derivative thereof; Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, O or S; PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and F and F' are end groups and/or are linked together by a covalent bond, and the physiologically tolerated salts thereof, a process for their preparation and their use as pharmaceutical, as gene probe and as primer, are described.

Description

Polyamide-oligonucleotide derivatives, their preparation and use

- 5 The present invention relates to novel polyamide-oligonucleotide derivatives with valuable physical, biological and pharmacological properties. Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and
10 triplex forming oligonucleotides), as probes for detecting nucleic acids and as aids in molecular biology.

Oligonucleotides are finding increasing application as inhibitors of gene expression (G. Zon, Pharmaceutical Research 5, 539 (1988); J.S. Cohen, Topics in Molecular
15 and Structural Biology 12 (1989) Macmillan Press; C. Helene and J.J. Toulme, Biochimica et Biophysica Acta 1049, 99 (1990); E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). Antisense oligonucleotides are nucleic acid fragments whose base sequence is complementary to that of an mRNA to be inhibited. This target mRNA
20 can be of cellular, viral or other pathogenic origin. Suitable cellular target sequences are, for example, those of receptors, cell-adhesion proteins, enzymes, immunomodulators, cytokines, growth factors, ion channels
25 or oncogenes. Inhibition of virus replication with the aid of antisense oligonucleotides has been described, for example, for HBV (hepatitis B virus), HSV-1 and -2 (herpes simplex virus type I and II), HIV (human immunodeficiency virus) and influenza viruses. This entails use
30 of oligonucleotides which are complementary to the viral nucleic acid. Sense oligonucleotides are, by contrast, designed to have a sequence such that, for example, they bind ("trap") nucleic acid-binding proteins or nucleic acid-processing enzymes and thus inhibit their biological
35 activity (C. Helen and J.J. Toulme, Biochimica t

Biophysica Acta 1049, 99 (1990)). Viral targets which may be mentioned here are, for example, reverse transcriptase, DNA polymerase and transactivator proteins. Triplex-forming oligonucleotides generally have the DNA as target and, after binding thereto, form a triple helix structure. Whereas in general the processing (splicing etc.) of the mRNA or translation thereof into protein is inhibited by antisense oligonucleotides, the transcription or replication of the DNA is inhibited by triplex-forming oligonucleotides (C. Helene and J.J. Toulme, *Biochim. Biophys. Acta* 1049 (1990) 99-125; E. Uhlmann and A. Peyman, *Chemical Reviews* 90, 543 (1990)). However, it is also possible to bind single-stranded nucleic acids in a first hybridization with an antisense oligonucleotide to form a double strand, which then in a second hybridization with a triplex-forming oligonucleotide forms a triplex structure. The antisense and triplex binding regions may in this case be accommodated either in two separate oligonucleotides or else in one oligonucleotide. Another application of synthetic oligonucleotides comprises so-called ribozymes which destroy the target RNA as a consequence of their ribonuclease activity (J.J. Rossi and N. Sarver, *TIBTECH* (1990) 8, 179; Castanetto et al., *Critical Rev. Eukar. Gene Expr.* (1992) 2, 331).

The compounds according to the invention can also be used in therapy in the sense of aptamers. Aptamers are oligomeric nucleic acids or analogs thereof which bind with high affinity to proteins. The aptamers are found by in vitro selection from a random mixture (Famulok and Szostak (1992) *Angew. Chem.* 104, 1001-1011) and this has been carried out successfully for a thrombin-binding aptamer (Bock et al. (1992) *Nature* 355, 564-566). The procedure for this can be such that the base sequence of the aptamer is determined by screening an oligonucleotide mixture, and this base sequence is then transferred to polyamide-oligonucleotide analogs. Another possibility comprises encoding the binding region of the aptamer, to

- 3 -

facilitate identification, by a separate non-binding part of the molecule (Brenner and Lerner (1992) PNAS 89, 5381-5383).

5 In DNA diagnosis, nucleic acid fragments with suitable labeling are used as so-called DNA probes for specific hybridization onto a nucleic acid to be detected. The specific formation of the new double strand is in this case followed with the aid of the labeling, which is preferably non-radioactive. It is possible in this way to
10 detect genetic, malignant or viral diseases or diseases caused by other pathogens.

Oligonucleotides in their naturally occurring form have little or no suitability for most of the said applications. They have to be chemically modified so that they
15 satisfy the specific requirements. For oligonucleotides to be employable in biological systems, for example for inhibition of virus replication, they must meet the following requirements:

1. They must have sufficiently high stability under in
20 vivo conditions, that is to say both in serum and intracellularly.
2. Their properties must be such that they can pass through the cell membrane and nuclear membrane.
3. Under physiological conditions they must bind in a
25 base-specific manner to their target nucleic acid in order to display the inhibitory effect.

Points 1 to 3 are not a requirement for DNA probes; however, these oligonucleotides must be derivatized so that detection is possible, for example by fluorescence,
30 chemiluminescence, colorimetry or specific staining (Beck and Köster, Anal. Chem. 62, 2258 (1990)). The chemical modification of the oligonucleotides usually takes place by appropriate modification of the phosphate backbone, ribose unit or the nucleotid bases (J.S. Cohen, Topics
35 in Molecular and Structural Biology 12 (1989) Macmillan Press; E. Uhlmann and A. Peyman, Chemical Reviews 90,

543 (1990)). Another frequently used method is to prepare oligonucleotide 5' conjugates by reaction of the 5'-hydroxyl group with appropriate phosphorylation reagents. If, on the other hand, all the internucleotide phosphate residues are modified there is often a drastic change in the properties of the oligonucleotides. For example, the solubility of methyl phosphonates in aqueous medium is greatly reduced, while all-phosphorothioate oligonucleotides often act in a non-sequence-specific manner.

There have recently been descriptions of polyamide-nucleic acid derivatives (Michael Egholm, Peter E. Nielsen, Rolf H. Berg and Ole Buchardt, Science 1991, 254, 1497-1500; WO 92/20702; M. Egholm et al. Nature (1993) 365, 566-568; P. Nielsen, (1994) Bioconjugate Chem. 5, 3-7) which bind to complementary target sequences (DNA or RNA) with higher affinity than natural oligonucleotides. These so-called peptide or polyamide nucleic acids (PNA) are DNA-analogous compounds in which the deoxyribose phosphate skeleton has been replaced by a polyamide oligomer. These compounds have the advantage compared with natural oligonucleotides that they are very stable in serum. However, on the other hand, they have the following disadvantageous properties:

- (1) The amount taken up in cells is zero or undetectable. However, since antisense or triplex-forming oligonucleotides are able to display their activity only in the cell, the PNAs as such are unsuitable for inhibition of gene expression in vivo.
- (2) The PNAs tend to aggregate in aqueous solution, that is to say also under physiological conditions. Their solubility in aqueous buffer is therefore low and they are unavailable for hybridization to complementary sequences.
- (3) The PNAs additionally have high affinity for various materials such as ®Sephadex (from Pharmacia) or ®Bond Elut (from Varian) used to purify the oligomers, so that the PNAs can often be isolated only in poor yields.

- 5 -

(4) Another serious disadvantage of the PNAs is that they do not bind in an unambiguous orientation to complementary nucleic acids. The sequence specificity is therefore reduced by comparison with natural oligonucleotides. Whereas natural nucleic acids generally hybridize to complementary nucleic acids in the antiparallel orientation, PNAs may bind both in the antiparallel and in the parallel orientation.

(5) WO 92/20702 mentions an oligonucleotide-PNA conjugate (T)₇(5'-L-N)(t)₆-Ala (Fig. 25; substitute sheet), where (T)₇ is a natural heptathymidylate oligonucleotide which is linked via its 5'-O-phosphate and 4-hydroxybutyric acid (L) to the primary amino group (N) of a PNA-hexathymidylate (t)₇ and alanine (Ala). Neither the synthesis of this compound nor any properties have been described.

(6) PNAs show highly cytotoxic properties in the μ molar range in cell culture experiments.

The orientation of the base-pairing nucleic acid strands is defined as follows: (cf. Egholm et al.; Nature 365 (1993) 566-568).

A)

5' ----- 3' DNA ap Duplex ap = antiparallel
3' ----- 5' DNA

B)

25 5' ----- 3' DNA p Duplex p = parallel
 5' ----- 3' DNA

C)

5' ----- 3' DNA ap Duplex (DNA·PNA)
C ----- N PNA

30 D)

5' ----- 3' DNA p Duplex (DNA·PNA)
N ----- C PNA

- 6 -

E)

C ----- N PNA
 5' ----- 3' DNA (Pu) ap·ap triplex (DNA·DNA·PNA)
 3' ----- 5' DNA Pu = purine-rich strand

5 F)

N ----- C PNA
 5' ----- 3' DNA (Pu) ap·p triplex (DNA·DNA·PNA)
 3' ----- 5' DNA

G)

10 N ----- C PNA
 5' ----- 3' DNA (Pu) ap·p triplex (PNA·DNA·PNA)
 C ----- N PNA

H)

C ----- N PNA
 15 5' ----- 3' DNA (Pu) ap·ap triplex (PNA·DNA·PNA)
 C ----- N' PNA

I)

N ----- C PNA
 5' ----- 3' DNA (Pu) p·p triplex (DNA·DNA·PNA)
 20 N ----- C' PNA

K)

C ----- N PNA
 5' ----- 3' DNA (Pu) p·ap triplex (DNA·DNA·PNA)
 N ----- C PNA

25 where 5' means the 5' end of an oligonucleotide,
 3' means the 3' end of an oligonucleotide,
 N means the amino terminus of a PNA
 C means the carboxyl terminus of a PNA.


Cases A)-D) are examples of the types of orientation
 30 which are possible in principle for the antisense oligo-
 mers. Cases E)-F) show possibilities for triplex forma-
 tion on single-stranded or double-stranded nucl ic acids.

- 7 -

It is moreover possible for two of the PNA or DNA single strands to be linked together. For example, in E) the N terminus of the PNA can be linked to the 5' end of the DNA, or in F) the C terminus of the PNA can be linked to the 5' end of the DNA.

The object of the invention therefore was to prepare polyamide-oligonucleotide derivatives in which the abovementioned disadvantages are eliminated.

The invention relates to polyamide-oligonucleotide derivatives of the formula I



wherein

- q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t ≥ 2 ;
- x is 1 to 20, preferably 1 to 5, particularly preferably 1;
- DNA is a nucleic acid such as DNA or RNA or a known derivative thereof;
- Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, O or S;
- PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and
- F and F' are end groups and/or are linked together by a covalent bond (cyclic compounds), and the physiologically tolerated salts thereof.

Particular mention may furthermore be made of polyamide-oligonucleotide derivatives of the formula I in which x is 1 and, at the same time,




q = r = 1 and s = t = zero or

r = s = 1 and q = t = zero or

q = r = s = 1 and t = zero or

$r = s = t = 1$ and $q = \text{zero}$.

Preferred compounds have the formulae Ia and Ib




in which


x is 1 to 20, where

5 when $x > 1$ $r = s = 1$ and, at the same time,
 $q = t = \text{zero}$ and $o = n = \text{zero}$ to 5;

- q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t ≥ 2 ;
- R² is hydrogen, hydroxyl, C₁-C₁₈-alkoxy, preferably C₁-C₆-alkoxy, halogen such as F or Cl, preferably F, azido or amino;
- B is, independently of one another, a base customary in nucleotide chemistry, for example natural bases such as adenine, cytosine, thymine, guanine, uracil, inosine or unnatural bases such as, for example, purine, 2,6-diaminopurine, 7-deazaadenine, 7-deazaguanine, N⁴,N⁴-ethanocytosine, N⁶,N⁶-ethano-2,6-diaminopurine, pseudoisocytosine, 5-methylcytosine, 5-fluorouracil, 5-(C₃-C₆)-alkynyluracil, 5-(C₃-C₆)-alkynylcytosine or the prodrug forms thereof, and the "curved bracket" indicates that R² and the adjacent substituent can be in the 2' position and 3' position or else conversely in the 3' position and 2' position;
- Nu is a radical of the formulae IIa or IIb



(IIa)



(IIb)


in which

R² and B are as defined above;


U is hydroxyl, mercapto, C₁-C₁₈-alkyl, preferably C₁-C₈-alkyl, C₁-C₁₈-alkoxy, preferably C₁-C₈-

alkoxy, C₆-C₂₀-aryl, preferably C₆-C₁₂-aryl, C₆-C₁₄-aryl-C₁-C₈-alkyl, preferably C₆-aryl-C₁-C₄-alkyl, NHR³ or NR³R⁴, and

R^3 is C_1 - C_{18} -alkyl or C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, preferably C_1 - C_8 -alkyl or C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, particularly preferably C_1 - C_4 -alkyl or methoxyethyl and
 R^4 is C_1 - C_{18} -alkyl, preferably C_1 - C_8 -alkyl and particularly preferably C_1 - C_4 -alkyl, or
 R^3 and R^4 is, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain another hetero atom from the series consisting of O, S, N, such as, for example, morpholine;
V is oxy, thio or imino;
W is oxo or thioxo;
Y is oxy, thio, methylene or imino;
m is zero to 20;
o is zero to 20;
D is a radical of the formula III



20 in which B is as defined above;
 D' is a radical of the formula IV




in which B is as defined above;

- 11 -

n is zero to 20;
 p is zero to 20;
 Li₁, Li₂, Li₃ and Li₄ are each, independently of one another, a structure of the formula V




where, independently of one another,
 e is 1 to 5, preferably 1-2,
 V' is oxygen, NH, a bond or a radical of the formula VI



10 in which
 U, V, W and Y are as defined above;
 G can be C₁-C₁₂-alkanediyl, preferably C₁-C₆-alkane-
 diyl, where alkanediyl can optionally be substituted
 by halogen, preferably F or chlorine, amino,
 15 hydroxyl, C₁-C₁₈-alkyl, preferably C₁-C₆-alkyl,
 C₁-C₁₈-alkoxy, preferably C₁-C₆-alkoxy, C₆-C₁₄-aryl,
 preferably C₆-aryl, or C₆-C₁₄-aryl-C₁-C₁₈-alkyl,
 preferably C₆-aryl-C₁-C₄-alkyl; C₆-C₁₄-aryl-di-C₁-
 C₁₂-alkanediyl, preferably C₆-aryl-di-C₁-C₄-alkane-
 20 diyl, or a group of the formula (CH₂CH₂O)_δCH₂CH₂ in
 which δ can be 1 to 11, preferably 1 to 7; or a
 bond; and
 G' is oxy, thio, imino, -C(O)-, -C(O)NH-, a bond or a
 radical of the formula VI in which U, V, W and Y are
 25 as defined above; and
 F and F' are linked by a bond (cyclic compounds) and/or
 F is R⁰ - (A)_x - V - and
 F' in formula Ia is - (Q)₁ - R¹ and in formula Ib is
 V¹ - (A)₁ - R¹,
 30 where
 R⁰ is hydrogen, C₁-C₁₈-alkanoyl, preferably C₈-C₁₈-

alkanoyl, C₁-C₁₈-alkoxycarbonyl, C₃-C₈-cycloalkanoyl, C₇-C₁₅-aroyl, C₃-C₁₃-heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or
 5 if k is zero, R⁰ is hydrogen or together with V is a radical of the formula VII



10 in which
 Z and Z' are, independently of one another, hydroxyl, mercapto, C₁-C₂₂-alkoxy, preferably C₁₂-C₁₈-alkoxy, C₁-C₁₈-alkyl, preferably C₁₂-C₁₈-alkyl, C₆-C₂₀-aryl, preferably C₆-C₁₆-aryl, C₆-C₁₄-
 15 aryl-C₁-C₁₈-alkyl, preferably C₆-aryl-C₁-C₄-alkyl, C₁-C₂₂-alkylthio, preferably C₁₂-C₁₈-alkylthio, NHR³, NR³R⁴, or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage, and in which
 20

R³, R⁴, V and W are as defined above;

R¹ is hydrogen or Q⁰

25 where R¹ is always only hydrogen when at the same time l is zero and in formula Ia t is zero and s is 1 and Li₁ is a structure of the formula V with V' = bond, G = bond, e = 1 and G' = oxy, thio, imino or a radical of the formula VI with U = Z

30 or

in formula Ib q is 1 or q = r = zero and in F' = V¹ - (A)₁ - R¹ with V¹ = V,

A and Q are, independently of one another, the

residue of a natural or unnatural amino acid, preferably from the series consisting of glycine, leucine, histidine, phenylalanine, cysteine, lysine, arginine, aspartic acid, glutamic acid, proline, tetrahydroisoquinoline-3-carboxylic acid, octahydroindole-2-carboxylic acid, N-(2-aminoethyl)glycine;
 5 Q^o is hydroxyl, OR' , NH_2 , NHR'' with

$R' = C_1-C_{18}$ -alkyl, preferably $C_{12}-C_{18}$ -alkyl and
 $R'' = C_1-C_{18}$ -alkyl, preferably $C_{12}-C_{18}$ -alkyl,
 10 C_1-C_{18} -aminoalkyl, preferably $C_{12}-C_{18}$ -aminoalkyl, C_1-C_{18} -hydroxyalkyl, preferably $C_{12}-C_{18}$ -hydroxyalkyl;

V is as defined above;

V^1 is a bond or V , where in F' only in formula Ib
 15 with $q = \text{zero}$ and $r = 1$ V^1 is always a bond;

k is zero to 10;

l is zero to 10;

with the proviso that

a) if in the compound of the formula Ia t is zero and
 20 s is 1, and Li_1 is $(V') - (G) - (G')$ with $V' =$ a compound of the formula VI, $G = C_2-C_{12}$ -alkylene and $G' = CO$, in $F' = - (Q)_1 - R^1$ l is zero to 10 and R^1 is Q^o ;

b) if in the compound of the formula Ia $s = t = \text{zero}$,
 25 Li_2 is a bond;

c) if in the compound of the formula Ib t is zero and
 s is 1, Li_3 is a bond;

d) if in the compound of the formula Ib $s = t = \text{zero}$,
 Li_4 is a bond;

30 where each nucleotide can be in its D or L configuration, and the base can be in the α or β position.

Particularly preferred compounds of the formula Ia and Ib are those in which the base is located on the sugar in the β position,

35 x is 1 and

$q = r = 1$, $s = t = \text{zero}$ or

$r = s = 1, q = t = \text{zero}$ or
 $q = r = s = 1, t = \text{zero}$ or
 $r = s = t = 1, q = \text{zero}.$

Especially preferred oligomers have the formulae Ia and
 5 Ib in which V', V, Y and W have the meaning of thio, oxy,
 oxo or hydroxyl; these are very particularly preferred
 if, in addition, R² is hydrogen.

Also especially preferred are oligomers of the formulae
 Ia and Ib with $e = 1$, in which

10 Li₁, Li₄ are

a) a compound of the formula V in which
 V' = oxygen or compound of the formula VI,
 G = C₁-C₁₀-alkylene, G' = -CONH-

15 b) a compound of the formula V in which G, V'
 is a bond and G' is a compound of the formula
 VI with, preferably, U = V = W = Y = oxygen or
 U = W = Y = oxygen and V = imino

Li₂, Li₃ are

20 a) a compound of the formula V with V' = imino,
 G = C₁-C₁₀-alkylene and G' = compound of the
 formula VI

b) a compound of the formula V with V' = imino,
 G and G' = bond

25 c) a compound of the formula V with V' = imino,
 G = C₁-C₁₀-alkylene and G' = V with, prefer-
 ably, U = V = W = Y = oxygen.

Very particularly preferred oligomers have the formulae
 Ia and Ib in which V', V, Y and W have the meaning of
 thio, oxy, oxo or hydroxyl, R² is hydrogen, Li₁ has the
 30 meaning of -V'-[CH₂]_nC(O)NH- with V' = compound of the
 formula VI with U = V = W = Y = oxygen or Li₂ has the
 meaning of -HN-[CH₂]_n(G')-, where n is 2 to 5 and G' has
 the formula VI with U, V, W and Y = oxygen.

Additionally preferred oligomers of the formula Ia and
 35 Ib are those in which V', V, Y and W have the meaning of

- 15 -

thio, oxy, oxo or hydroxyl, R^2 is hydrogen, Li_1 has the meaning of $-O-[CH_2]_n C(O)NH-$ or Li_2 has the meaning of $-HN-[CH_2]_n (G')-$, where n is 2 to 5 and G' has the formula VI with U , V , W and $Y =$ oxygen, and $q =$ zero and
 5 $r = s = t = 1$.

Additionally preferred are oligomers of the formulae Ia and Ib in which the curved bracket means that R^2 is in the 3' position (see formula IIb). The preferred base in this case is adenine.

10 The invention is not confined to α - and β -D- and L-ribofuranosides, α - and β -D- and L-deoxyribofuranosides and corresponding carbocyclic five-membered ring analogs but also applies to oligonucleotide analogs which are composed of different sugar building blocks, for example
 15 ring-expanded and ring-contracted sugars, acyclic, ring-bridged or other suitable types of sugar derivatives. The invention is furthermore not confined to the derivatives, indicated by way of example in formula I, of the phosphate residue but also relates to known dephospho
 20 derivatives.

The oligonucleotide part (DNA in formula I) can therefore be modified from the natural structure in a wide variety of ways. Examples of such modifications, which are introduced by methods known per se, are:

25 a) Modifications of the phosphate bridge
 Examples which may be mentioned are: phosphorothioates, phosphorodithioates, methylphosphonates, phosphoramidates, boranophosphates, phosphate methyl esters, phosphate ethyl esters, phenylphosphonates. Preferred
 30 modifications of the phosphate bridge are phosphorothioates, phosphorodithioates and methylphosphonates.

b) Replacement of the phosphat bridg

Examples which may be mentioned ar : replac ment by formacetal, 3'-thioformacetal, methylhydroxylamin ,

oxime, methylenedimethylhydrazo, dimethylene sulfone, silyl groups. Replacement by formacetals and 3'-thioformacetals is preferred.

c) Modifications of the sugar

- 5 Examples which may be mentioned are: α -anomeric sugars, 2'-O-methylribose, 2'-O-butylribose, 2'-O-allylribose, 2'-fluoro-2'-deoxyribose, 2'-amino-2'-deoxyribose, α -arabinofuranose, carbocyclic sugar analogs. The preferred modification is that by 2'-O-methylribose and
10 2'-O-n-butylribose.

d) Modifications of the bases with do not alter the specificity of the Watson-Crick base pairing

- Examples which may be mentioned are: 5-propynyl-2'-deoxyuridine, 5-propynyl-2'-deoxycytidine, 5-hexynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxycytidine, 5-fluoro-2'-deoxycytidine, 5-fluoro-2'-deoxyuridine, 5-hydroxymethyl-2'-deoxyuridine, 5-methyl-2'-deoxycytidine, 5-bromo-2'-deoxycytidine. Preferred modifications are 5-propynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxycytidine and 5-propynyl-2'-deoxycytidine.
20


e) 3'-3' and 5'-5' inversions [for example M. Koga et al., J. Org. Chem. 56 (1991) 3757]

f) 5'- and 3'-phosphates, and 5'- and 3'-thiophosphates.

- Examples of groups which favor intracellular uptake are
25 various lipophilic radicals such as $-O-(CH_2)_x-CH_3$ in which x is an integer from 6 to 18, $-O-(CH_2)_n-CH=CH-(CH_2)_m-CH_3$ in which n and m are, independently of one another, an integer from 6 to 12, $-O-(CH_2CH_2O)_4-(CH_2)_9-CH_3$, $-O-(CH_2CH_2O)_8-(CH_2)_{13}-CH_3$ and $-O-(CH_2CH_2O)_7-(CH_2)_{15}-CH_3$, but
30 also steroid residues such as cholesteryl or vitamin residues such as vitamin E, vitamin A or vitamin D and other conjugates which utilize natural carrier systems such as bil acid, folic acid, 2-(N-alkyl-N-alkoxyamino)-anthraquinone and conjugates of mannose and peptides of


- 17 -

th appropriat receptors which lead to receptor-mediated endocytosis of the oligonucleotides, such as EGF (Epidermal Growth Factor), bradykinin and PDGF (Platelet Derived Growth Factor). By labeling groups are meant
5 fluorescent groups, for example of dansyl (= 1-dimethyl-aminonaphthalene-5-sulfonyl), fluorescein or coumarin derivatives or chemiluminescent groups, for example of acridine derivatives, and the digoxigenin system detectable by ELISA, the biotin group detectable by the
10 biotin/avidin system or else linker arms with functional groups which permit subsequent derivatization with detectable reporter groups, for example an aminoalkyl linker which is reacted with an acridinium active ester to give the chemiluminescence probe. Typical labeling
15 groups are:




Fluorescein derivative

- 18 -



Acridinium ester




x = 2-18 preferably 4

R = H or C₁-C₄-alkyl[= "Fluorescein" for x = 4 and R = CH₃]


Fluorescein derivative

R = H or amino protective group





Biotin conjugate (= "Biotin" for R = Fmoc)

- 19 -




Digoxigenin conjugate


Oligonucleotide analogs which bind to or intercalate and/or cleave or crosslink nucleic acids contain, for example, acridine, psoralen, phenanthridine, naphtho-
 5 quinone, daunomycin or chloroethylaminoaryl conjugates. Typical intercalating and crosslinking radicals are:

Acridine derivative $x = 2-12$, preferably 4 $x = 2-12$, preferably 4


- 20 -




Trimethylpsoralene conjugate (- "psoralene" for x=O)



Phenanthroline conjugate




Psoralen conjugate




Naphthoquinone conjugate


- 21 -



Daunomycin derivative



$x = 1-18$, $X = \text{Alkyl, Halogen, NO}_2, \text{CN, } \begin{array}{c} \text{-C-R} \\ || \\ \text{O} \end{array}$




$x = 1-18$, $X = \text{Alkyl, Halogen, NO}_2, \text{CN, } \begin{array}{c} \text{-C-R} \\ || \\ \text{O} \end{array}$

Examples which may be mentioned of NR^3R^4 groups in which R^3 and R^4 form, together with the nitrogen atom carrying them, a 5- to 6-membered heterocyclic ring which additionally contains another hetero atom are the morpholinyl
5 and the imidazolidinyl radical.

The polyamide part (PNA in formula I) is composed of amid structures which contain at least on nucl tide


base which is different from thymine. Polyamide structures of this type are composed, for example, of the following building blocks a) to h), preferably a), in which f is 1 to 4, preferably 1 or 2 and g is zero to 3, preferably zero to 2:

a)




Hyrup et al.; J. Chem. Soc. Chem. Comm. 1993, 519

b)




De Konig et al. (1971) Rec. Trav. Chim. 91, 1069

10 c)




Huang et al. (1991) J. Org. Chem. 56, 6007

d)




Almarsson et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 7518

e)




Froehler et al. (1991) WO 93/10820

f)




Froehler et al. (1991) WO 93/10820

5 g)



Lewis (1993) Tetrahedron Lett. 34, 5697.

h)



End groups for PNAs are described in the applications, filed simultaneously, with the titles "PNA synthesis using an amino protective group which is labile to weak acids" (HOE 94/F 060, DE-P 44 08 531.1) and "PNA synthesis using a base-labile amino protective group" (HOE 94/F 059, DE-P 44 08 533.8).

- 24 -

Preferred polyamide structures are composed of structures according to a). The latter are particularly preferred when f is 1.

5 The preparation of polyamide-oligonucleotide derivatives of the formula I takes place similarly to the synthesis of oligonucleotides in solution or, preferably, on solid phase, where appropriate with the assistance of an automatic synthesizer. The oligomer of the formula I can be assembled stepwise by successive condensation of one
10 PNA unit or DNA unit with in each case one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain. However, the assembly can also take place in fragment fashion, in which case the fragments are first synthesized as polyamide or oligonucleotide structures which are then linked to give the
15 polyamide-oligonucleotide of the formula I. However, it is also possible to use building blocks composed of PNA and nucleotide, preferably dimers, which are then assembled by the methods of nucleotide chemistry or
20 peptide chemistry to give polyamide-oligonucleotide derivatives.

The assembly of the oligonucleotide part takes place by processes known to the skilled worker, such as the triester method, the H-phosphonate method or phosphoramidite method, preferably by the standard phosphoramidite chemistry of Caruthers (M.D. Matteucci and M.H. Caruthers, J. Am. Chem. Soc. 103, 3185 (1981)). The polyamide part can be synthesized by the methods of peptide chemistry known to the skilled worker. If the
25 oligonucleotide part and polyamide part are not separately synthesized and subsequently linked, the processes used to assemble the oligonucleotide structure and polyamide structure must be mutually compatible, in which connection a preferred embodiment of the synthesis of the
30 polyamide part is described in the simultaneously filed application with the title "PNA synthesis using an amino

- 25 -

protective group which is labile to weak acids"
(HOE 94/F 060, DE-P 44 08 531.1).

Depending on whether q, r, s and t are 1 or zero, the
synthesis starts with the oligonucleotide part or with
5 the polyamide part. The synthesis of compounds of the
formula I whose oligonucleotide part is modified at the
3' and/or at the 5' end takes place in respect of these
modifications by the processes described in
EP-A 0 552 766 (HOE 92/F 012) (compare synthetic scheme
10 for DNA). The synthesis of compounds of the formula I
takes place in respect of the polyamide part by the
process described in the simultaneously filed application
with the title "PNA synthesis using an amino protective
group which is labile to weak acids (HOE 94/F 060, DE-P
15 44 08 531.1) (compare synthetic scheme for PNA).

Synthetic scheme for DNA

- [anchor group]-[polymer]
1. | coupling on of PG-(Nu')-active
PG-(Nu')-[anchor group]-[polymer]
 - 20 2. | elimination of protective group PG
H-(Nu')-[anchor group]-[polymer]
 3. | repetition of steps 1 and 2 (n-1) times
H-(Nu')_n-[anchor group]-[polymer]
 4. | coupling on of R⁰-V-active
25 R⁰-V-(Nu')_n-[anchor group]-[polymer]
 5. | elimination of polymer and protective groups
R⁰-V-(Nu)_n

Synthetic scheme for PNA

- [anchor group]-[polymer]
- 30 1. | coupling on of PG-(Q')-OH
PG-(Q')-[anchor group]-[polymer]
 2. | elimination of protective group PG
H-(Q')-[anchor group]-[polymer]
 3. | repetition of steps 1 and 2 (l-1) times
H-(Q')₁-[anchor group]-[polymer]
 - 35 4. | coupling on of PG-[B'/X]-OH

- PG-[B'/X]-(Q')₁-[anchor group]-[polymer]
5. | elimination of protective group PG
 H-[B'/X]-(Q')₁-[anchor group]-[polymer]
6. | repetition of steps 4 and 5 (n-1) times
- 5 H-[B'/X]_n-(Q')₁-[anchor group]-[polymer]
7. | coupling on of PG-(A')-OH
 PG-(A')-[B'/X]_n-(Q')₁-[anchor group]-[polymer]
8. | elimination of protective group PG
 H-(A')-[B'/X]_n-(Q')₁-[anchor group]-[polymer]
- 10 9. | repetition of steps 7 and 8 (k-1) times
 H-(A')_k-[B'/X]_n-(Q')₁-[anchor group]-[polymer]
10. | coupling on of the group R⁰
 R⁰-(A')_k-[B'/X]_n-(Q')₁-[anchor group]-[polymer]
11. | elimination of polymer and protective groups
- 15 R⁰-(A)_k-[B/X]_n-(Q)₁-Q⁰

The meanings in this are:

PG protective group, preferably a protective group labile to weak acid;

20 Nu' nucleotide unit whose exocyclic amino group is protected by a suitable protective group;

Nu'-active an activated derivative customary in nucleotide chemistry, such as, for example, of a phosphoramidite, a phosphodiester or an H-phosphonate;

25 A', B' and Q' are the forms of A, B and Q which are protected where appropriate.

Synthetic scheme for PNA/DNA hybrids of the formula I



For $q = r = s = t = 1$ and $x = 1$, the following outline of the synthesis applies:

- 30 1. | synthesis of the end group F'; where appropriate conjugation to polymer
 PG-F'
2. | limination of protective group PG
 H-F'

- 27 -

3. | conjugation of the polyamide structur
 PNA-F'
4. | coupling on of a linker
 Li-PNA-F'
- 5 5. | conjugation of the nucleotide structure
 DNA-Li-PNA-F'
6. | coupling on of a linker
 Li-DNA-Li-PNA-F'
7. | repetition of steps 3 to 5
- 10 DNA-Li-PNA-Li-DNA-Li-PNA-F'
8. | coupling on of the end group F
 F-DNA-Li-PNA-Li-DNA-Li-PNA-F'

The coupling on of the linker building block can be omitted if appropriate junctions are present in the PNA or DNA building blocks.

For clarification, a synthetic scheme for PNA/DNA hybrids of the formula I is shown and explains by way of example the preparation of a hybrid oligomer in which $q = r = s = t = 1$ and $x = 1$. Initially, the end group F is synthesized by known processes and, in the case of solid-phase synthesis, coupled to a polymeric support (step 1). After elimination of the protective group PG (step 2), which preferably takes place in weakly acidic medium, the polyamide building blocks are coupled on to the desired length of the PNA part (step 3). As junction to the DNA part it is now possible to attach a linker unit (step 4). The conjugation of the nucleotide structure then takes place by successive condensation on of the nucleotide building blocks (step 5), preferably by the known phosphoramidite method. After a linker which makes it possible to join DNA to PNA has been condensed on (step 6), in turn a polyamide structure is assembled. Introduction of a linker which makes it possible to join PNA to DNA, conjugation of another DNA structure (step 7) and final coupling on of the end group F (step 8) result in the hybrid molecule [F-DNA-Li-PNA-Li-DNA-Li-PNA-F']. The linker building blocks can in this case also

- 28 -

contain nucleotide bases. To synthesize a hybrid F-DNA-Li-PNA-Li-F' ($q = r = 1$, $s = t = \text{zero}$), for example first steps 1-5 are carried out and then the synthesis is completed with step 8.

- 5 To synthesize a hybrid F-PNA-Li-DNA-F' ($r = s = 1$, $q = t = \text{zero}$), for example first steps 1-2 are carried out, then steps 5-6 follow, followed by step 3 and completion of the synthesis with step 8.

- 10 To synthesize a hybrid F-PNA-Li-DNA-Li-PNA-F' ($r = s = t = 1$, $q = \text{zero}$), the synthesis starts with steps 1-6. After repetition of step 3, the synthesis is completed with step 8.

- 15 If x in formula I is > 1 , then steps 2-7 must be repeated where appropriate. After assembly of the polymeric chains, the PNA/DNA hybrids must in the case of solid-phase synthesis be cleaved off the support and, where appropriate, the protective groups on the bases, amino-acid side chains and end groups must be eliminated.

- 20 However, the PNA part and DNA part can also be synthesized separately by known methods and subsequently coupled together via appropriate activation of at least one component. Activation of the PNA part preferably takes place via the carboxylic acid group, for example as active ester or isothiocyanate, which are then reacted
25 with reactive groups in the DNA part, preferably an amino group. Activation of the DNA part takes place, for example, in the form of a cyanogen bromide condensation known per se, in which the activated phosphate functionality is reacted with a reactive group in the PNA
30 part, preferably an amino group.

It has been found, surprisingly, that the oligomers of the formula Ia and Ib have a greatly increased cellular uptake by comparison with pure PNAs. This improved cellular uptake is very crucial because antisense- or

triplex-forming oligomers are able to act only if they are efficiently taken up by cells. Their hybridization behavior is likewise more favorable than in the case of pure PNAs because they preferentially lead to anti-parallel duplex formation. Compared with normal oligonucleotides, they have an improved nuclease stability, which is expressed by an increased biological activity. The binding affinity to complementary nucleic acids is better than the other nuclease-stable oligonucleotides such as, for example, phosphorothioates or methylphosphonates. The binding affinity of the compounds according to the invention is at least equally good, but usually better, by comparison with natural oligonucleotides, which are rapidly degraded under serum conditions. The increase in the binding affinity depends on the length of the PNA part. Pure PNAs showed a potent cytotoxic effect at concentrations $> 5 \mu\text{M}$ in cell-culture experiments, whereas the compounds according to the invention did not damage the cells. It has furthermore been found that compounds of the formula I inhibit, depending on the base sequence of the PNA part and DNA part, the expression of specific genes, for example of enzymes, receptors or growth factors, in cell culture and in selected examples in animal models.

Further advantages of the PNA/DNA oligomers and PNA/RNA oligomers comprise the possibility of stimulating cellular endonucleases such as, for example, RNase H and RNase L. In contrast to PNAs, the PNA-DNA chimeras according to the invention which have some deoxyribonucleotide units are able, after binding to the complementary target RNA, to cleave the latter in a sequence-specific manner owing to induction of cellular RNase H. A particular embodiment of the oligomers according to the invention furthermore comprises those which are composed of PNA part and a 2',5'-linked oligoadenylate part, preferably tetraadenylate or its cordycepin analog, and which activate cellular RNase L.

- 30 -

The present invention extends very generally to the use of compounds of the formula I as therapeutically active ingredients of a pharmaceutical. By therapeutically active polyamide-oligonucleotide derivatives is meant in
5 general antisense oligonucleotides, triple helix-forming oligonucleotides, aptamers or ribozymes, especially antisense oligonucleotides.

The pharmaceuticals of the present invention can be used, for example, to treat diseases caused by viruses, for
10 example by HIV, HSV-1, HSV-2, influenza, VSV, hepatitis B or papilloma viruses.

Antisense polyamide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence. The
15 length and position of the PNA part and DNA part in these sequences can be altered appropriately to achieve optimal properties.

a) against HIV, for example

5'-A C A C C C A A T T C T G A A A A T G G-3' OR
20 (I)

5'-A G G T C C C T G T T C G G G C G C C A-3' OR
(II)

5'-G T C G A C A C C C A A T T C T G A A A A T G G A T A A-3' OR
(III)

25 5'-G C T A T G T C G A C A C C C A A T T C T G A A A-3' OR
(IV)

5'-T C G T C G C T G T C T C G C T T C T T C T T C C T G C C A OR
(VI)

b) against HSV-1, for example

- 31 -

5'-G C G G G G C T C C A T G G G G G T C G-3'
(VII)

The pharmaceuticals of the present invention are also suitable, for example, for the treatment of cancer. In this connection, it is possible to use, for example, polyamide-oligonucleotide sequences which are directed against targets which are responsible for the development of cancer or the growth of cancers. Examples of such targets are:

- 10 1) nuclear oncoproteins such as, for example, c-myc, N-myc, c-myb, c-fos, c-fos/jun, PCNA, p120
- 2) cytoplasmic/membrane-associated oncoproteins such as, for example, EJ-ras, c-Ha-ras, N-ras, rrg, bcl-2, cdc-2, c-raf-1, c-mos, c-src, c-abl
- 15 3) cellular receptors such as, for example, the EGF receptor, c-erbA, retinoid receptors, protein kinase regulatory subunit, c-fms
- 4) cytokines, growth factors, extracellular matrix such as, for example, CSF-1, IL-6, IL-1a, IL-1b, IL-2, IL-4,
- 20 bFGF, myeloblastin, fibronectin.

Antisense polyamide-oligonucleotides of the formula I according to the invention which are active against such targets have, for example, the following base sequence:

a) against c-Ha-ras, for example

25 5'-C A G C T G C A A C C C A G C-3'
(VIII)

c) c-myc, for example

5'-G G C T G C T G G A G C G G G G C A C A C-3'
(IX)

- 32 -

5'-A A C G T T G A G G G G C A T-3'
(X)

d) c-myb, for example

5'-G T G C C G G G G T C T T C G G G C-3'
5 (XI)

e) c-fos, for example

5'-G G A G A A C A T C A T G G T C G A A A G-3'
(XII)

5'-C C C G A G A A C A T C A T G G T C G A A G-3'
10 (XIII)

5'-G G G G A A A G C C C G G C A A G G G G-3'
(XIV)

f) p120, for example

5'-C A C C C G C C T T G G C C T C C C A C-3'
15 (XV)

g) EGF receptor, for example

5'-G G G A C T C C G G C G C A G C G C-3'
(XVI)

5'-G G C A A A C T T T C T T T T C C T C C-3'
20 (XVII)

h) p53 tumor suppressor, for example

5'-G G G A A G G A G G A G G A T G A G G-3'
(XVIII)

5'-G G C A G T C A T C C A G C T T C G G A G-3'
25 (XIX)

The pharmaceuticals of the present invention are further suitable, for example, for the treatment of diseases which are influenced by integrins or cell-cell adhesion receptors, for example by VLA-4, VLA-2, ICAM, VCAM or ELAM.

Antisense polyamide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence:

a) VLA-4, for example

10 5'-G C A G T A A G C A T C C A T A T C-3' OR
(XX)

b) ICAM, for example

5'-C C C C C A C C A C T T C C C C T C T C-3'
(XXI)

15 5'-C T C C C C C A C C A C T T C C C C T C-3'
(XXII)

5'-G C T G G G A G C C A T A G C G A G G-3'
(XXIII)

c) ELAM-1, for example

20 5'-A C T G C T G C C T C T T G T C T C A G G-3'
(XXIV)

5'-C A A T C A A T G A C T T C A A G A G T T C-3'
(XXV)

The pharmaceuticals of the present invention are also suitable, for example, for preventing restenosis. In this connection, examples of polyamide-oligonucleotide sequences which can be used are those directed against targets which are responsible for proliferation or migration. Examples of such targets are:

1) nuclear transactivator proteins and cyclins such as, for exampl , c-myc, c-myb, c-fos, c-fos/jun, cyclins and cdc2 kinase

2) mitogens or growth factors such as, for example, PDGF, bFGF, EGF, HB-EGF and TGF- β

3) cellular receptors such as, for example, bFGF receptor, EGF receptor and PDGF receptor.

Antisense polyamide-oligonucleotides according to the invention of the formula I which are active against such targets have, for example, the following base sequence:

a) c-myb

5'-G T G T C G G G G T C T C C G G G C-3'
(XXVI)

b) c-myc

5'-C A C G T T G A G G G G C A T-3'
(XXVII)

c) cdc2 kinase

5'-G T C T T C C A T A G T T A C T C A-3'
(XXVIII)

d) PCNA (proliferating cell nuclear antigen of rat)

5'-G A T C A G G C G T G C C T C A A A-3'
(XXIX)

The pharmaceuticals can be used, for example, in the form of pharmaceutical products which can be administered orally, for example in the form of tablets, coated tablets, hard or soft gelatin capsules, solutions, emulsions or suspensions. Inclusion of the pharmaceuticals in liposomes, which optionally contain further components

such as proteins, is a likewise suitable administration form. They can also be administered rectally, for example in the form of suppositories, or parenterally, for example in the form of injection solutions. To produce
5 pharmaceutical products, these compounds can be processed in therapeutically inert organic and inorganic excipients. Examples of such excipients for tablets, coated tablets and hard gelatin capsules are lactose, corn starch or derivatives thereof, talc and stearic acid or
10 salts thereof. Suitable excipients for producing solutions are water, polyols, sucrose, invert sugar and glucose. Suitable excipients for injection solutions are water, alcohols, polyols, glycerol and vegetable oils. Suitable excipients for suppositories are vegetable and
15 hardened oils, waxes, fats and semiliquid polyols. The pharmaceutical products may also contain preservatives, solvents, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, salts to alter the osmotic pressure, buffers, coating agents, antioxidants
20 and, where appropriate, other therapeutic active substances.

Preferred administration forms are topical applications, local applications such as, for example, with the aid of a catheter or else injections. For injection, the
25 antisense polyamide-oligonucleotide derivatives are formulated in a liquid solution, preferably in a physiologically acceptable buffer such as, for example, Hank's solution or Ringer's solution. The antisense polyamide-oligonucleotides can, however, also be formulated in
30 solid form and be dissolved or suspended before use. The dosages preferred for systemic administration are about 0.01 mg/kg to about 50 mg/kg of body weight and day.

The invention extends very generally to the use of compounds of the formula I as DNA probes or primers in
35 DNA diagnosis, in particular in the sense of the gen probes mentioned in HOE 92/F 406 (EP-A 0 602 524), and generally as aids in molecular biology.

Gene probes, also called DNA probes or hybridization probes, play a large part in DNA diagnosis for sequence-specific detection of particular genes. A gene probe is generally composed of a recognition sequence and of a suitable labeling group (label). The specificity of the determination of a target sequence in an analytical sample by hybridization with a complementary gene probe is determined by the recognition sequence and its chemical structure. The PNAs have the advantage, compared with oligonucleotides of natural structure, that they have a higher affinity for the target sequence. However, the specificity of the hybridization is reduced because PNAs, in contrast to natural DNA, are able to bind both in parallel and in antiparallel orientation to single-stranded nucleic acids. The PNA/DNA oligomers according to the invention likewise show an increased binding affinity but very preferentially bind in the desired antiparallel orientation.

It is moreover possible, by appropriate selection of the PNA part and DNA part in a gene probe, to have a beneficial effect on the differentiation capacity because base mispairing in the PNA part leads to a greater depression of the melting temperature of a hybrid than does a base mispairing in the DNA part. This is particularly important with regard to differentiation in the case of point mutations as occur, for example, in the transition from protooncogenes into the corresponding oncogenes (pathogenic state). The advantage of the better discrimination between pathogenic and non-pathogenic state can also be utilized in the form of the primer property of the PNA/DNA oligomers according to the invention as long as these have a free 3'-hydroxyl group in the DNA part. PNAs as such have no primer function for polymerases. It has been found, surprisingly, that even one nucleoside unit at the end of a PNA/DNA oligomer is sufficient to initiate the DNA polymerase reaction, for example with DNA polymerase (Klenow fragment). Various polymerases can be employed depending on the characteris-

tics of the PNA/DNA primer and the nature of the template onto which the primer hybridizes in a sequence-specific manner. These polymerases are generally commercially available, such as, for example, Taq polymerase, Klenow polymerase or reverse transcriptase.

Another advantage by comparison with the use of natural oligonucleotide primers is that the nucleic acid strand which is copied with the aid of the PNA/DNA primer and which contains the PNA part at the 5' end is stable to 5'-exonucleases. It is thus possible to degrade all natural DNA or RNA sequences in the reaction mixture by 5'-exonucleases without attack on the PNA-containing strand.

Another advantage of the PNA/DNA oligomers is that they can also be used to carry out other biochemical reactions on the DNA part which are impossible with PNAs themselves. Examples of such reactions are the 3'-tailing with 3'-terminal transferase, the digestion with restriction enzymes in the DNA double-stranded region, and ligase reactions. For example, a (PNA)-(DNA)-OH oligomer with free 3'-hydroxyl group can be linked to a second p-(DNA)-(PNA) oligomer which contains a nucleoside 5'-phosphate at the 5' end after hybridization to a complementary DNA auxiliary sequence of natural origin in the presence of a DNA ligase.

(DNA)-(PNA)-(DNA) oligomers can furthermore be incorporated into genes, which is not at present possible with PNAs.

The linkage of labeling groups onto PNA/DNA oligomers takes place by methods known per se, as described for oligonucleotides or peptides. The nature of the labeling group can vary within wide limits and depends essentially on the type of assay used. Known embodiments of gene probe assays are the hybridization protection assay, the energy transfer assay and the kissing probe assay.

- 38 -

PNA/DNA oligomers are additionally particularly suitable for a strand displacement assay. In many cases it is advantageous to remove the hybrid which is formed from excess gene probe with the aid of magnetic particles. The stability of the PNA/DNA gene probes according to the invention is higher than that of conventional DNA probes.

Polymerase chain reaction (PCR) and ligase chain reaction (LCR) are techniques for target amplification in which the oligomers according to the invention can likewise be used as primers. The PNA/DNA oligomers can be used particularly advantageously as gene probes on the Christmas tree principle because in this case the PNA/DNA probes can be shorter than corresponding DNA probes.

Examples:

The abbreviations used for amino acids correspond to the three-letter code customary in peptide chemistry, as described in Europ. J. Biochem. 138, 9 (1984). Other abbreviations used are listed below.

	Aeg	N-(2-Aminoethyl)glycyl,
20		-NH-CH ₂ -CH ₂ -NH-CH ₂ -CO-
	Aeg(a ^{MeOBz})	N-(2-Aminoethyl)-N-(N ⁶ -(4-methoxybenzoyl)-9-adenosylacetyl)-glycyl
	Aeg(c ^{Bz})	N-(2-Aminoethyl)-N-(N ⁴ -benzoyl-1-cytosylacetyl)-glycyl
25	Aeg(c ^{MeOBz})	N-(2-Aminoethyl)-N-(N ⁴ -(4-methoxybenzoyl)-1-cytosylacetyl)-glycyl
	Aeg(c ^{tBuBz})	N-(2-Aminoethyl)-N-(N ⁴ -(4-tert.butylbenzoyl)-1-cytosylacetyl)-glycyl
	Aeg(g ^{iBu})	N-(2-Aminoethyl)-N-(N ² -isobutanoyl-9-guanosylacetyl)-glycyl
30	Aeg(g ^{2-Ac,4-Dpc})	N-(2-Aminoethyl)-N-(N ² -acetyl-O ⁴ -diphenylcarbamoyl-9-guanosyl)glycyl
	Aeg(t)	N-(2-Aminoethyl)-N-((1-thyminy)acetyl)-glycyl
35	Bnpeoc	2,2-[bis(4-Nitrophenyl)]-ethoxycarbonyl
	Boc	tert.-butoxycarbonyl

	BOI	2-(Benzotriazol-1-yloxy)-1,3-dimethyl-imidazolidinium hexafluorophosphate
	BOP	Benzotriazolyl-1-oxy-tris(dimethylamino)-phosphonium hexafluorophosphate
5	BroP	Bromo-tris(dimethylamino)phosphonium hexafluorophosphate
	BSA	N,O-bis(Trimethylsilyl)-acetamide
	But	tert.-butyl
	Bz	Benzoyl
10	Bzl	Benzyl
	Cl-Z	4-Chloro-benzyloxycarbonyl
	CPG	Controlled pore glass
	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
	DCM	Dichloromethane
15	Ddz	2-(3,5-Dimethoxyphenyl)-2-propyloxycarbonyl
	DMF	Dimethylformamide
	Dmt	di-(4-Methoxyphenyl)phenylmethyl
	Dnpeoc	2-(2,4-Dinitrophenyl)-ethoxycarbonyl
20	Dpc	Diphenylcarbamoyl
	FAM	Fluorescein residue
	Fm	9-Fluorenylmethyl
	Fmoc	9-Fluorenylmethyloxycarbonyl
	H-Aeg-OH	N-(2-Aminoethyl)glycine
25	HAPyU	O-(7-Azabenzotriazol-1-yl)-1,1,3,3-bis-(tetramethylene)uronium hexafluorophosphate
	HATU	O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
30	HBTU	O-(Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	HOBT	1-Hydroxybenzotriazole
	HONSu	N-Hydroxysuccinimide
	HOObt	3-Hydroxy-4-oxo-3,4-dihydrobenzotriazine
35	iBu	Isobutanoyl
	MeOBz	4-Methoxybenzoyl
	Mmt	4-Methoxytriphenylmethyl
	Moz	4-Methoxybenzyloxycarbonyl

	MSNT	2-Mesitylenesulfonyl-3-nitro-1,2,4-triazole
	Mtt	(4-Methylphenyl)diphenylmethyl
	NBA	Nitrobenzyl alcohol
5	NMP	N-Methylpyrrolidine
	Obg	N-(4-Oxybutyl)glycyl, -O-(CH ₂) ₄ -NH-CH ₂ -CO-
	Obg(t)	N-(4-Oxybutyl)-N-((1-thyminy)l)acetyl)-glycyl
	Oeg	N-(2-Oxyethyl)glycyl,
10		-O-CH ₂ -CH ₂ -NH-CH ₂ -CO-
	Oeg(t)	N-(2-Oxyethyl)-N-((1-thyminy)l)acetyl)-glycyl
	Opeg	N-(5-Oxypentyl)glycyl,
		-O-(CH ₂) ₅ -NH-CH ₂ -CO-
15	Opeg(t)	N-(5-Oxypentyl)-N-((1-thyminy)l)acetyl)-glycyl
	Oprg	N-(3-Oxypropyl)glycyl,
		-O-(CH ₂) ₃ -NH-CH ₂ -CO-
	Oprg(t)	N-(3-Oxypropyl)-N-((1-thyminy)l)acetyl)-glycyl
20	Pixyl	9-(9-Phenyl)xanthenyl
	PyBOP	Benzotriazolyl-1-oxytripyrrolidinophosphonium hexafluorophosphate
	PyBroP	Bromotripyrrolidinophosphonium hexafluorophosphate
25	TAPipU	O-(7-Azabenzotriazol-1-yl)-1,1,3,3-bis-(pentamethylene)uronium tetrafluoroborate
	TBTU	O-(Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
30	tBu	tert.-Butyl
	tBuBz	4-tert. Butylbenzoyl
	TDBTU	O-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
35	TDO	2,5-Diphenyl-2,3-dihydro-3-oxo-4-hydroxythiophene dioxide
	Teg	N-(2-Thioethyl)glycyl,
		-S-CH ₂ -CH ₂ -NH-CH ₂ -CO-

- 41 -

	Teg(t)	N-(2-Thioethyl)-N-((1-thyminy)acetyl)-glycyl
	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
5	TNTU	O-(5-Norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluronium tetrafluoroborate
	TOTU	O-[(Cyano(ethoxycarbonyl)methylene)-amino]-1,1,3,3-tetramethyluronium tetrafluoroborate
10	TPTU	O-(1,2-Dihydro-2-oxo-1-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
	Trt	Trityl
	TSTU	O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
15	Z	Benzyloxycarbonyl
	MS(ES ⁺)	Electrospray mass spectrum (positive ion)
	MS(ES ⁻)	Electrospray mass spectrum (negative ion)
	MS(DCI)	Desorption chemical ionization mass spectrum
20	MS(FAB)	Fast atom bombardment mass spectrum

Example 1

1-Hydroxy-6-((4-methoxyphenyl)-diphenylmethylamino)-hexane

25 Mmt-hex

6-Amino-1-hexanol (1 g; 8.55 mmol) is dissolved in anhydrous pyridine (7 ml), and triethylamine (0.2 ml) is added. To this solution is added over the course of 45 minutes a solution of (4-methoxyphenyl)diphenylmethyl chloride (2.5 g; 8.12 mmol) in anhydrous pyridine (9 ml). The reaction solution is stirred further at 22°C for 30 minutes and stopped by adding methanol (3 ml). The solution is concentrated in a rotary evaporator, and the resulting residue is coevaporated with toluene three times to remove the pyridine. The resulting residue is dissolved in ethyl acetate, and this solution is washed successively with a saturated sodium bicarbonate solu-

- 42 -

tion, with water and with a saturated potassium chloride solution. The organic phase is dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product is purified

5 triethylamine/49.5:49.5:1.

Yield: 1.64 g

MS (FAB, NBA/LiCl) 396.3 ($\text{M} + \text{Li}$)⁺, 390.3 ($\text{M} + \text{H}$)⁺, 273.2 (Mmt)⁺

R_f 0.44 (heptane:ethyl acetate = 1:1)

10 Example 2

6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexyl hemi-succinate

Mmt-hex-succ

1-Hydroxy-6-((4-methoxyphenyl)diphenylmethylamino)hexane
15 (1.00 g; 2.57 mmol) is dissolved in anhydrous pyridine (10 ml). To this solution are added succinic anhydride (0.257 g; 2.57 mmol) and 4-dimethylaminopyridine (31.3 mg; 0.257 mmol). After stirring at 22°C for 3 hours, further succinic anhydride (25.7 mg; 0.257 mmol)
20 and 4-dimethylaminopyridine (62.6 mg; 0.56 mmol) are added, and this solution is heated at 50°C for 6 hours. After a further 16 hours at 22°C, the mixture is concentrated, the residue is taken up in ethyl acetate, and the resulting solution is washed with ice-cold 5% strength
25 aqueous citric acid. After the org. phase has been dried (Na_2SO_4), the solution is concentrated in a rotary evaporator. Purification of the residue by silica gel chromatography using 50% CH_2Cl_2 /1% triethylamine in ethyl acetate and then using 5% methanol/1% triethylamine in
30 dichloromethane affords the required compound as colorless oil.

MS (ES^-) 978.0 ($2\text{M}-\text{H}$)⁻, 488.3 ($\text{M}-\text{H}$)⁻

R_f 0.30 (CH_2Cl_2 :ethyl acetate = 1:1).

Example 3

6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexylsuccinyl-amido-Tentagel
(Mmt-hex-succ-Tentagel)

- 5 The amino form of Tentagel^R (Rapp polymers) (0.5 g; 0.11 mmol amino groups) is left to swell in 4-ethylmorpholine (0.1 ml) and DMF (5 ml) for 10 minutes. A solution of 6-((4-methoxyphenyl)diphenylmethylamino)-1-hexyl hemisuccinate (97.4 mg; 0.165 mmol), 4-ethylmorpholine
10 (15.9 mg; 0.138 mmol; 17.4 ml) and TBTU (52.9 mg; 0.165 mmol) in DMF (3 ml) is then added, and the suspension is shaken at 22°C for 16 hours. The derivatized Tentagel support is filtered off and washed successively with DMF (3 × 3 ml), CH₂Cl₂ (3 × 1 ml) and diethyl ether
15 (3 × 1 ml) and dried. Unreacted amino groups are blocked by treatment with acetic anhydride/lutidine/1-methylimidazole in THF (1 ml) for 1 hour. The completed support is washed with CH₂Cl₂ (3 × 1 ml) and diethyl ether (3 × 1 ml) and dried in vacuo. Based on the monomethoxytrityl group introduced, the loading is 168 mmolg⁻¹.
20

Example 4

6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexylsuccinylamidopropyl-controlled pore glass.
(Mmt-hex-succ-CPG)

- 25 The preparation takes place in analogy to the description in Example 3 starting from aminopropyl-CPG (supplied by Fluka) (550 Angstrom; 1.0 g) and 6-((4-methoxyphenyl)-diphenylmethylamino)-1-hexyl hemisuccinate (48.7 mg; 0.082 mmol), 4-ethylmorpholine (7.6 ml) and TBTU
30 (26.4 mg; 0.082 mmol) in DMF (3 ml). The loading of the Mmt-hex-succCPG is 91 mmolg⁻¹.

Example 5

N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N⁴-(4-tert-butylbenzoyl)-1-cytosylacetyl)glycine
(Mmt-Aeg(c^{tBuBz})-OH)

- 5 1.63 g (2.28 mmol) of N-((4-methoxyphenyl)diphenylmethylamino)ethyl-N-(N⁴-(4-tert-butylbenzoyl)-1-cytosylacetyl)-glycine methyl ester were dissolved in a mixture of 10 ml of dioxane and 1 ml of water and, while stirring at 0°C, 4.56 ml of 1 N NaOH were added dropwise. After 2 h, the
10 pH was adjusted to 5 by dropwise addition of 1 N KHSO₄, and precipitated salts were filtered off and washed with a little dioxane. The combined filtrates were evaporated in vacuo, and the residue was coevaporated twice with methanol and dichloromethane. The crude product obtained
15 in this way was purified by chromatography on silica gel using a gradient of 2-10% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. Excess triethylamine still present was removed by coevaporation with
20 pyridine and then toluene. 0.831 g of product was obtained as an almost white foam.

Electrospray MS (negative ion) 700.7 (M-H)⁻.

R_f 0.28 (CH₂Cl₂:MeOH/9:1), 0.63 (CH₂Cl₂:MeOH/7:3).

Example 6

- 25 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-((1-thyminy)acetyl)glycine
(Mmt-Aeg(t))-OH

- The product from the above reaction was dissolved in a mixture of 10 ml of dioxane and 2 ml of water, the
30 solution was cooled to 0°C, and 1 N sodium hydroxide solution was added dropwise until the pH reached 11. After a reaction time of 2 h, the reaction was complete and the solution was adjusted to pH 5 by cautious addition of 2 N KHSO₄ solution. The solution was extracted
35 three times with ethyl acetate, and the combined organic phases were dried over sodium sulfate and concentrated in

- 45 -

vacuo. The crude product obtained in this way was purified by chromatography on silica gel using a gradient of 5-10% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. Excess triethylamine still present was removed by coevaporation with pyridine and then toluene. 1.065 g of product were obtained as a colorless foam.

Electrospray MS (negative ion) 1112.0 (2M-H)⁻, 555.3 (M-H)⁻
R_f 0.28 (CH₂Cl₂:MeOH/8:2).

Example 7

N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N²-isobutanoyl-9-guanosylacetyl)glycine
(Mmt-Aeg(g^{iBu})-OH

N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N²-isobutanoyl-9-guanosylacetyl)glycine methyl ester (1.15 g; 1.72 mmol) is dissolved in dioxane (10 ml) and, at 0°C, 1 M aqueous sodium hydroxide solution (10.32 ml) is added dropwise in 5 portions over a period of 2.5 h. After a further reaction time of 2 h at room temperature, the solution is adjusted to pH 5 by dropwise addition of 2 M aqueous potassium bisulfate solution. The precipitated salts are filtered off and washed with a little dioxane. The combined filtrates are evaporated to dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1 dichloromethane:methanol. Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloromethane (with 1% triethylamine). The product is obtained as a white foam.

Yield: 1.229 g

ESMS (negative ion): 650.3 (M-H)⁻R_f 0.25 (dichloromethane:methanol/8:2)

Example 8

N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N⁶-(4-methoxybenzoyl)-9-adenosylacetyl)glycine
(Mmt-Aeg(a^{MeOBz})-OH)

- 5 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N⁶-(4-methoxybenzoyl)-9-adenosylacetyl)glycine methyl ester (1.70 g; 2.38 mmol) is dissolved in dioxane (10 ml) and, at 0°C, 1 M aqueous sodium hydroxide solution (10.32 ml) is added dropwise in 5 portions over a period
10 of 2.5 h. After a further reaction time of 2 h at room temperature, the solution is adjusted to pH 5 by dropwise addition of 2 M aqueous potassium bisulfate solution. The precipitated salts are filtered off and washed with a little dioxane. The combined filtrates are evaporated to
15 dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1 dichloromethane:methanol. Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloromethane (with 1% triethylamine). The product
20 is obtained as a white foam.

Yield: 1.619 g

ESMS (negative ion): 698.3 (M-H)⁻

R_f 0.10 (dichloromethane:methanol/8:2)

Example 9

- 25 N-((4-Methoxyphenyl)diphenylmethoxy)ethyl-N-((1-thyminy)l)acetyl)glycine
(Mmt-Oeg(t)-OH)

- 0.5 g (1.28 mmol) of N-((4-methoxyphenyl)diphenylmethoxy)ethylglycine was suspended in 10 ml of DMF, and
30 0.47 ml (1.92 mmol) of BSA was added dropwise. Then, 0.7 ml (5.1 mmol) of triethylamine and 0.26 g (1.28 mmol) of chlorocarboxymethylthymine were successively added. The reaction mixture was stirred at room temperature for 4 h and then a further 65 mg (0.32 mmol) of chlorocarboxymethylthymine were added, and the mixture was stirred
35 for 16 h. The solvent was then stripped off in vacuo, and

- 47 -

the crude product was purified on a silica gel column using a gradient of 5-15% m thanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. The resulting
5 brownish oil was dissolved in a little dichloromethane, and the product was precipitated by adding diethyl ether. The product was obtained as an almost white powder.
Yield: 0.219 g
Electrospray MS (negative ion) 556.3 (M-H)⁻.
10 R_f 0.54 (CH₂Cl₂:MeOH/8:2).

Example 10

4-Nitrophenyl 4-(4,4'-dimethoxytrityloxy)butyrate
Dmt-but-NPE

The sodium salt of 4-hydroxybutyric acid (1.26 g;
15 10 mmol) is dissolved in anhydrous pyridine (30 ml), and 4,4'-dimethoxytrityl chloride (3.39 g; 3.05 mmol) is added. After 16 hours, 4-nitrophenol (1.39 g; 10 mmol) and N,N'-dicyclohexylcarbodiimide (2.06 g; 10 mmol) are added, and the mixture is stirred at 22°C for a further
20 48 hours. The precipitated dicyclohexylurea is filtered off and washed with dichloromethane. The filtrate is concentrated and the resulting residue is coevaporated twice with toluene. The residue is purified on a silica gel column (10-50% ethyl acetate and 1% triethylamine in
25 petroleum ether). The desired compound is obtained in the form of a pale yellowish-colored oil.

Yield: 2.694 g

MS (FAB, MeOH/NBA/LiCl) 534.2 (M + Li)⁺, 527.2 M⁺.

R_f 0.34 (petroleum ether:ethyl acetate = 75:25)

30 Example 11

H-Oprg(t)-OH

3.68 g of thymynylacetic acid are dissolved in 20 ml of dry DMF, and 6.65 g of TOTU and 2.77 ml of triethylamine
ar added. The mixture is stirred at room temperature for
35 30 min and then slowly added dropwise to a solution

composed of 5.32 g of (3-hydroxypropyl)glycin , 20 ml of water, 20 ml of DMF and 5.54 ml of triethylamine. The mixture is stirred at room temperature for 1 h and then concentrated in a rotary evaporator in vacuo. The residue
5 is taken up in water, adjusted to pH 1.5 with 1 N hydrochloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarbonate solution and concentrated in a rotary evaporator. The residue is mixed with 250 ml of ethanol, and
10 the sodium chloride precipitated thereby is filtered off with suction. The filtrate is concentrated and the crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine followed by dichloromethane/
15 methanol/ethyl acetate 10:4:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.

Yield: 3.2 g

20 R_f 0.15 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine)
MS(ES^+): 300.2 ($M + H$)⁺.

Example 12

Dmt-Oprg(t)-OH

25 3.2 g of H-Oprg(t)-OH are dissolved in 40 ml of DMF, 5.93 ml of triethylamine are added and, at 0°C, a solution of 7.25 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 20 min. The mixture is stirred at room temperature for 2 h, then the precipitated triethylamine hydrochloride is filtered off, and the
30 filtrate is concentrated in a rotary evaporator in vacuo. The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
35 The crude product is purified on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The fractions containing

- 49 -

the product are combined and concentrated in a rotary evaporator in vacuo.

Yield: 3.46 g

R_f 0.28 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine)

MS (ES^+) 602.4 ($M + H$) $^+$.

Example 13

H-Obg(t) OH

2.76 g of thyminyllactic acid are dissolved in 15 ml of dry DMF, and 4.92 g of TOTU and 2.08 ml of triethylamine are added. The mixture is stirred at room temperature for 30 min and then slowly added dropwise to a solution composed of 4.41 g of (4-hydroxybutyl)glycine, 10 ml of water, 10 ml of DMF and 4.16 ml of triethylamine. The mixture is stirred at room temperature for 3 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydrochloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarbonate solution and concentrated in a rotary evaporator. The crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.

Yield: 3.7 g

R_f 0.11 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine)

MS (ES^+) 314.2 ($M + H$) $^+$.

Example 14

Dmt-Obg(t)-OH

3.6 g of H-Obg(t)-OH are dissolved in 40 ml of DMF, 9.5 ml of triethylamine are added and, at 0°C, a solution of 15.4 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 15 min. The mixture is

Yield: 3.34 g

R_f 0.19 (dichloromethane/methanol/ethyl acetat 10:2:1
+ 1% triethylamine)

MS (DCI) 328.2 (M + H)⁺.

5 Example 16

Dmt-Opeg(t)-OH

3.2 g of H-Opeg(t)-OH are dissolved in 40 ml of DMF,
6.77 ml of triethylamine are added and, at 0°C, a solu-
tion of 9.94 g of Dmt-Cl in 40 ml of dichloromethane is
10 added dropwise over the course of 15 min. The mixture is
stirred at room temperature for 2 h, a further 40 ml of
dichloromethane are added, then the precipitated
triethylamine hydrochloride is filtered off, and the
filtrate is concentrated in a rotary evaporator in vacuo.
15 The residue is taken up in dichloromethane and extracted
with water, and the organic phase is dried with sodium
sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using
dichloromethane/methanol/ethyl acetate 15:1:1 with the
20 addition of 1% triethylamine. The fractions containing
the product are combined and concentrated in a rotary
evaporator in vacuo.

Yield: 3.6 g

R_f 0.27 (dichloromethane/methanol/ethyl acetate 10:2:1
25 + 1% triethylamine)


MS (ES⁺ + LiCl) 636.4 (M + Li)⁺.


Example 17

5'-ATC GTC GTA TT-(but)-agtc-hex

The DNA sequence is indicated in capital letters and the
30 PNA sequence is indicated in small letters (example of
the structural type XIIa in scheme 1). The PNAs are
synthesized, for example, in an Ecosyn D-300 DNA synthe-
sizer (from Eppendorf/Biotronik, Maintal) or an ABI 380B
DNA synthesizer (from Applied Biosystems, Weiterstadt).
35 The synthesis of the DNA part is carried out in principle


by standard phosphoramidite chemistry and commercially obtainable synthesis cycles. For the synthesis of the PNA part the methods of peptide synthesis are approximated to the DNA synthesis cycles as explained hereinafter.






Formula X (Xa, V-D; Xb, V-NH)

- 54 -




Formula VIII

	R ⁵	R ⁶	R ²	V
VIII a	NC-CH ₂ CH ₂ -O-	-N(i-C ₃ H ₇) ₂	H	O
VIII b	CH ₃	-N(i-C ₃ H ₇) ₂	H	O
VIII c	C ₆ H ₅	-N(i-C ₃ H ₇) ₂	H	O
VIII d	C ₆ H ₅ -C(O)-S(CH ₂) ₂ -S	-N-pyrrolidin-1-yl	H	O
VIII e	NC-CH ₂ CH ₂ -O-	-N(i-C ₃ H ₇) ₂	OCH ₃	O
VIII f	NC-CH ₂ CH ₂ -O-	-N(i-C ₃ H ₇) ₂	H	NH




Formula IX (IXa, V=NH; IXb, V=O)


- 55 -

with $n = 1-8$, preferably 1-5,

Formula XIV



Formula XV



Formula XVI

- 56 -

3 μ mol of the CPG support loaded with Mmt-hex-succ (loading 91 μ mol/g) from Example 4 are treated successively with the following reagents:

Synthesis of the PNA part (agtc-hex):

- 5 1. dichloromethane
2. 3% trichloroacetic acid in dichloromethane
3. acetonitrile abs.
4. 3.5 M solution of 4-ethylmorpholine in acetonitrile (neutralization)
- 10 5. 0.4 M solution of (Mmt-Aeg(c^{tBuBz})-OH) from Example 5 in acetonitrile:DMF = 9:1/0.9 M solution of ByBOP in acetonitrile/3.5 M solution of 4-ethylmorpholine in acetonitrile (coupling time of 10 minutes).
6. step 5 is repeated four times.
- 15 7. acetonitrile

Steps 1 to 7, called a PNA reaction cycle hereinafter, are repeated 3 times to assemble the PNA part, using in step 5 in each case the monomer building block, necessary according to the sequence, from Examples 5 to 8.

- 20 Conjugation of the linker (agtc-hex ---> (but)-agtc-hex):
8. repeat steps 1 to 4 from above
9. 4-nitrophenyl 4-(4,4'-dimethoxytrityloxy)butyrate (105 mg) from Example 10 and hydroxybenzotriazole (27 mg) in 2 ml of NEM in DMF for 15 hours
- 25 10. wash with DMF
11. wash with acetonitrile
12. dichloromethane

Synthesis of the DNA part

((but)-agtc-hex) --> 5'-ATC GTC GTA TT-(but)-agtc-hex):

- 30 13. acetonitrile abs.
14. 3% trichloroacetic acid in dichloromethane
15. acetonitrile abs.
16. 10 μ mol of β -cyanoethyl 5'-O-dimethoxytritylthymidine 3'-diisopropylphosphoramidite and 50 μ mol of tetrazole in 0.3 ml of acetonitrile abs.
- 35

17. acetonitrile
18. 20% acetic anhydride in THF with 40% lutidine and 10% dimethylaminopyridine
19. acetonitrile
- 5 20. iodine (1.3 g in THF/water/pyridine; 70:20:5 = v:v:v)

Steps 13 to 20, called a DNA reaction cycle hereinafter, are repeated 10 times to assemble the nucleotide part, using in step 16 in each case the β -cyanoethyl 5'-O-dimethoxytrityl(nucleotide base) 3'-diisopropylphosphoramidite corresponding to the sequence.

After the synthesis is complete, the dimethoxytrityl group is eliminated as described in steps 1 to 3. The oligomer is cleaved off the support and, at the same time, the β -cyanoethyl groups are eliminated by treatment with ammonia for 1.5 hours. To eliminate the exocyclic amino protective groups, the ammoniacal solution is kept at 55°C for 5 hours. 180 OD₂₆₀ of the resulting crude product (325 OD₂₆₀) of 5'-ATC GTC GTA TT-(but)-agtc-hex are purified by polyacrylamide gel electrophoresis. Desalting on a Biogel^R column (from Biorad) results in 50 OD₂₆₀ of high-purity oligomer from this.

Example 18

5'-ATC GTC GTA TT-(Oeg(t))-agtc-hex

- 25 (Example of structural type Xa in scheme 2; see Example 9 for explanation of Oeg(t))

The synthesis takes place in analogy to the description in Example 17 but in step 9 coupling the linker building block Mmt-Oeg(t)-OH from Example 9, in place of the p-nitrophenyl Dmt-butyrate, under the conditions described in step 5. 135 OD₂₆₀ of the resulting crude product (235 OD₂₆₀) of 5'-ATC GTC GTA TT-(Oeg(t))-agtc-hex are purified by polyacrylamide gel electrophoresis. Desalting on a Biogel^R column (from Biorad) results in 20 OD₂₆₀ of high-purity oligomer from this.

Example 19

N-ggg g(5'NH-C)T C_SC_SA_S TGG GG_SG_S T (sequenc complemen-
tary to HSV-1)

(Example of structural type XI in scheme 2; _S means a
5 phosphorothioate bridge; (5'NH-C) means a 5'-aminocytidy-
late residue; N equals amino terminus)

The synthesis takes place starting from a CPG support on
which 5'-Dmt-thymidine is bound via its 3' end. The
synthesis of the DNA part is first carried out as
10 described in Example 17 (steps 13 to 20), carrying out
the oxidation in step 20 in the case of the phosphoro-
thioate bridges (_S) using tetraethylthiuram disulfide
(TETD; User Bulletin No. 65 of Applied Biosystems Inc.).
A Dmt-protected 5'-amino-5'-deoxycytidylate 3'-phosphor-
15 amidite building block of the formula VIIIIf is used as
linker building block. The PNA building blocks are then
condensed on in analogy to steps 1 to 7 in Example 17.
After the synthesis is complete, the oligomer is cleaved
off the support and, at the same time, the β-cyanoethyl
20 groups are eliminated by treatment with ammonia for
1.5 hours. To eliminate the exocyclic amino protective
groups, the ammoniacal solution is kept at 55°C for
5 hours. Only then is the monomethoxytrityl group elimi-
nated by treatment with 80% strength acetic acid at 22°C
25 for 2 hours. The product is purified by polyacrylamide
gel electrophoresis and desalted on a Biogel^R column
(from Biorad).

Example 20

5'-G_{Me}G_{Me}G GCT CCA (Oeg(t))gg ggg t-hex

30 (Example of structural type Xa in scheme 2; _{Me} means a
methylphosphonate bridge; see Example 9 for explanation
of Oeg(t))

The synthesis takes place in analogy to the description
in Examp1 18 but using the appropriate m thylphosphonate
35 building blocks of the formula VIIIf in the DNA reaction
cycle to incorporate the methylphosphonate bridges _{Me}.

- 59 -

Example 21

5'-C_S,_SA_S,_SC GT_S,_ST GAG (but)Ggg cat-hex (c-myc antisense)
 (Example of structural type XIIa in scheme 1; _S,_S means a
 phosphorodithioate bridge).

- 5 The synthesis takes place in analogy to the description
 in Example 17 but the building block VIIId is used to
 incorporate the dithioate bridges, and the oxidation at
 these sites (step 20) is carried out with TETD.

Example 22

- 10 N-cga g(5'NH-A)A CAT CA (Oeg(t))ggt cg-hex (c-fos
 antisense)
 (5'NH-A means 5'-amino-5'-deoxyadenylate; see Example 9
 for explanation of Oeg(t))

- The synthesis takes place in analogy to the description
 15 in Example 18 with, after completion of the DNA syn-
 thesis, in analogy to Example 13 condensation on of a
 5'-aminonucleotide which permits conjugation of the
 second PNA part. Thus, firstly six PNA synthesis cycles
 are carried out and then the linker building block from
 20 Example 9 is coupled on. Then seven DNA synthesis cycles
 are carried out, using the building block of the formula
 VIIIf in the last cycle. After a further four PNA syn-
 thesis cycles have been carried out, the elimination from
 the support and further working up are carried out as
 25 described in Example 19.

Example 23

- F-cga g(5'NH-A)A CAT CAT GGT _SC_SG-O-CH₂CH(OH)CH₂-O-C₁₆H₃₃
 (5'NH-A means 5'-amino-5'-deoxyadenylate; F a fluorescein
 residue on the amino terminus of the PNA and _S a
 30 phosphorothioate bridge)

The synthesis takes place in analogy to the description
 in Example 19 but starting from a CPG support onto which
 the glycerol hexadecyl ether is bound. After 12 DNA
 synthesis cycles have been carried out, the linker

- 60 -

building block VIIIIf is condensed on. After four PNA synthesis cycles have been carried out and the terminal Mmt group has been eliminated, it is possible to react the free amino group quantitatively with a 30-fold excess of fluorescein isothiocyanate (FITC).

Example 24

3'-CCC TCT T-5'-(PEG)(PEG)-(Oeg(t))tg tgg g-hex
(PEG means a tetraethylene glycol phosphate residue)

The synthesis in respect of the PNA part takes place in analogy to the description in Example 17. After six PNA units have been condensed on, the (Mmt-Oeg(t)-OH) from Example 9 is coupled on. Then as linker initially the tetraethylene glycol derivative of the formula XV is condensed on twice as described in the DNA synthesis cycle before the synthesis of the DNA part with reversed orientation (from 5' to 3') is carried out. For this purpose, in place of the nucleoside 3'-phosphoramidites in each case the corresponding nucleoside 5'-phosphoramidites of the formula XIV, which are commercially available, are used in step 16 in the DNA synthesis cycles. Further deprotection and working up take place as described in Example 17.

Example 25

N-ccc tct t-(C6-link)(PEG)-3'-AAG AGG G-5'
(PEG means a tetraethylene glycol phosphate residue;
C6-link is a 6-aminohexanol phosphate residue)

The synthesis takes place in analogy to the description in Example 17 (DNA synthesis cycle) but starting from a CPG support to which 3'-O-Dmt-deoxyguanosine is bound via a 5'-O-succinate group. After six DNA units have been condensed on using the building blocks of the formula XIV, initially the tetraethylene glycol derivative of the formula XV is condensed on once as linker before coupling the phosphoramidite of the formula XVI to introduce C6-link. The PNA part is then synthesized on as in

- 61 -

Example 17 (PNA synthesis cycle). Further deprotection and working up take place as described in Example 19.

Example 26

5'-TTT TTT TTT (but) ttt ttt-hex

- 5 The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA hybrid is taken for fluorescence labeling (Example 27). The other half is deprotected and worked up as described in Example 17.
- 10

Example 27

(FAM is fluorescein residue)

5'-FAM-TTT TTT TTT (but) ttt ttt-hex

- The support-bound DNA/PNA hybrid from Example 26 is fluorescence labeled by carrying out steps 13 to 20 as described in Example 17 using the fluorescein phosphoramidite from Applied Biosystems in step 16.
- 15

Example 28

5'-GGG GGG GGG (but) ttt ttt-hex

- 20 The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA hybrid is taken for fluorescence labeling (Example 29). The other half is deprotected and worked up as described in Example 17. The title compound binds as triplex-forming oligonucleotide with high affinity to a DNA double strand which contains the homopurine motif 5'-AAA AAA GGG GGG GGG-3'.
- 25

- 62 -

Example 29

(FAM is fluorescein residue)

5'-FAM-GGG GGG GGG (but) ttt ttt-hex

5 The support-bound DNA/PNA hybrid from Example 28 is fluorescence labeled by carrying out steps 13 to 20 as described in Example 17 using the fluoresceine phosphoramidite from Applied Biosystems in step 16.

Example 30

10 Biotin-C_{Phe}G_{Phe}A GAA cat ca t(5'NH-G)G(Ome)U(Ome)C(Ome)-G(Ome)-VitE (c-fos antisense)

(N(Ome) means a nucleotide unit N with a 2'-O-methoxy group; _{Phe} means a phenylphosphonate bridge; 5'NH-G means 5'-amino-5'-deoxyguanylate).

15 The synthesis takes place in analogy to the description in Example 17 starting from CPG which is loaded with vitamin E (MacKellar et al. (1992) Nucleic Acids Res, 20(13), 3411-17) and coupling the building block of the formula VIIIe four times after the DNA synthesis cycle. After the 5'-aminonucleotide building block of the
20 formula VIIIIf has been coupled on, six PNA units are condensed on after the PNA synthesis cycle. After neutralization, the phosphoramidite is coupled to the amino group by a known method, and the DNA synthesis cycle is repeated appropriately to assemble the DNA part, using in
25 the case of the phenylphosphonate bridges the building blocks of the formula VIIIfc in step 16. Lastly the end group is coupled on using the biotin phosphoramidite from Glen Research. After the synthesis is complete, the oligomer is deprotected as described in Example 19,
30 eliminating the dimethoxytrityl group at the end by treatment with 80% strength acetic acid at 22°C for 2 hours.

Exempl 31

A CAT CA (Oeg(t)) ggt cg-hex (c-fos antisense)
(See Example 9 for explanation of Oeg(t))

5 The synthesis takes place in analogy to the description
in Example 18. In this case, firstly five PNA synthesis
cycles are carried out and then the linker building block
Oeg(t) from Example 9 is coupled on. Then six DNA syn-
thesis cycles are carried out. Subsequently, the elimi-
nation from the support and the further working up are
10 carried out as described in Example 18.

Example 32

A TAA TG (Oeg(t)) tct cg-hex (control oligomer for c-fos)

15 The synthesis takes place in analogy to the description
in Example 18. In this case, firstly five PNA synthesis
cycles are carried out and then the linker building block
Oeg(t) from Example 9 is coupled on. Then six DNA syn-
thesis cycles are carried out. Subsequently, the elimi-
nation from the support and the further working up are
carried out as described in Example 18.

20 Example 33

a cat cat ggt cg-hex (c-fos antisense)

This pure PNA oligomer was prepared as reference compound
in analogy to Example 18 but with the exception that
twelve PNA cycles were carried out. Deprotection of the
25 exocyclic amino protective groups is carried out in
ammoniacal solution (5 hours at 55°C). Only then is the
monomethoxytrityl group eliminated by treatment with 80%
strength acetic acid at 22°C for 2 hours.

Example 34

30 A (5-hexy-C)A(5-hexy-U) (5-hexy-C)A (Oeg(t)) ggt cg-hex
(c-fos antisense)
(See Example 9 for explanation of Oeg(t); 5-hexy-C means
5-hexynylcytidine, 5-hexy-U means 5-hexynyluridine)

- 64 -

The synthesis takes place in analogy to the description in Example 31 but using in place of the normal pyrimidine phosphoramidites the corresponding 5-hexynylpyrimidine nucleoside phosphoramidites in the condensation reaction.

5 Example 35

(FAM is fluorescein residue)

5'-FAM-TT (but) ttt ttt-hex

The synthesis of this PNA/DNA oligomer takes place in analogy to the description in Example 27 although only
10 two thymidylate units are condensed on.

Example 36

taa tac gac tca cta (5'HN-T)

(5'HN-T means 5'-amino-5'-deoxythymidine)

This PNA/DNA oligomer which is composed of 15 PNA units
15 and one nucleoside unit was synthesized as primer for the DNA polymerase reaction. This entails starting from a solid phase support (aminoalkyl-CPG) to which the 5'-monomethoxytritylamino-5'-deoxythymidine is bound via its 3'-hydroxyl group as succinate. After elimination
20 of the monomethoxytrityl group with 3% TCA in dichloromethane, 15 PNA cycles are carried out as described in Example 17. Deprotection of the exocyclic amino protective groups is carried out in ammoniacal solution (5 hours at 55°C). Only then is the monomethoxytrityl
25 group eliminated by treatment with 80% strength acetic acid at 22°C for 2 hours. A PNA/DNA oligomer with a free 3'-hydroxyl group, which is used as primer for a DNA polymerase (Klenow) is obtained.

Example 37

30 p_s-rA(2'5')rA(2'5')rA(2'5')rA-spacer-(Oeg(t)tc ctc ctg cgg-hex

(p_s means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; rA is a riboadenylate; (2'5') means that the internucleotide linkage is from 2' to 5' in the

ribose)

The synthesis of this compound takes place in analogy to the description in Example 18 by initially condensing on 14 PNA units. After the linker building block
 5 Mmt-Oeg(t)-OH from Example 9 has been introduced under the conditions described in step 5, the Mmt group is eliminated with 3% TCA, and the spacer is introduced with the aid of the commercially available Dmt-O-(CH₂CH₂O)₃-O-P(-OCH₂CH₂CN)N(i-C₃H₇)₃ spacer phosphoramidite (from
 10 Eurogentech; Brussels). The (2'5')-linked tetradenylate is synthesized on as described in Example 17 using the commercially available N⁶-benzoyl-5'-O-Dmt-3'-O-tert-butyl-
 15 dimethylsilyl-adenosine 2'-O-cyanoethyl diisopropyl-aminophosphoramidite (from Milligen, Bedford, USA), extending the condensation time to 2 x 5 min. The stronger activator 5-ethylthiotetrazole is used in place of tetrazole in the coupling reaction. After elimination of the last Dmt group, the oligomer is phosphitylated on the 5'-OH group with bis(β-cyanoethoxy)diisopropyl-
 20 aminophosphine. Oxidation with TETD and deprotection with ammonia and desilylation with fluoride result in the title compound, which stimulates RNase L.

Example 38

p_S-Co(2'5')Co(2'5')Co(2'5')Co-spacer-(Oeg(t))tc ctc ctg
 25 cgg-hex

(p_S means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; Co is cordycepin (3'-deoxyadenosine); (2'5') means that the internucleotide linkage is from 2' to 5')

30 The synthesis is carried out in analogy to Example 37 but in place of the N⁶-benzoyl-5'-O-Dmt-3'-O-tert-butyl-dimethylsilyl-adenosine 2'-O-cyanoethyl diisopropyl-aminophosphoramidite, the corresponding N⁶-benzoyl-5'-O-Dmt-cordycepin 2'-O-cyanoethyl diisopropylaminophosphorami-
 35 dite (from Chemogen, Konstanz) is used, and the fluoride treatment is omitted.

- 66 -

Example 39

5'-GG GGG GGG (Oeg(t)) ttt ttt ttt-hex

The synthesis takes place in analogy to the description in Example 18, following nine PNA couplings by condensation on of the linker building block Mmt-Oeg(t)-OH from Example 9 under the conditions described in step 5, which permits subsequent condensation of eight guanylate residues. The resulting PNA/DNA oligomer binds with high affinity in the antiparallel orientation as triplex-forming oligonucleotide to double-stranded DNA which has the sequence 5'..AAAAAAAAAAGGGGGGGG..3'.

Example 40

Characterization of the PNA/DNA hybrids

The characterization takes place with the aid of HPLC, polyacrylamide gel electrophoresis (PAGE) and negative ion electrospray mass spectrometry (ES-MS⁻). The products are purified as described above and thereafter show in the PAGE (20% acrylamide, 2% bisacrylamide and 7 M urea) a single band. The HPLC takes place on RP-18 reversed phase columns from Merck (eluent A: water with 0.1% TFA, B: water/acetonitrile = 1:4; linear gradient) or on a PA-100 column from Dionex (eluent A: 20 mM NaOH and 20 mM NaCl; B: 20 mM NaOH and 1.5 M NaCl; linear gradient). For the ES-MS⁻, the PNA/DNA hybrids are converted by ammonium acetate precipitation or other metathesis into the ammonium salts. Sample introduction takes place from a solution in acetonitrile/water (1:1) containing 5 OD₂₆₀/ml oligomer. The accuracy of the method is about ± 1.5 Dalton.

30 Example 41

Determination of cellular uptake and stability after radioactive labeling

Radioactive labeling:

A generally applicable labeling with ³⁵S comprises

- 67 -

carrying out at least one oxidation in the DNA synthesis cycle (step 20 in Examp1 17) for the synthesis of the DNA part using elemental sulfur-35. PNA/DNA hybrids which have a free 5'-hydroxyl group can be labeled with ^{32}P or ^{35}S with the aid of polynucleotide kinase by methods known per se. PNA/DNA hybrids which carry a free 3'-hydroxyl group can be labeled in a known manner with 3'-terminal transferase. As an example, the 5'-labeling of the DNA part is described here: the PNA/DNA hybrid with a free 5'-hydroxyl group (500 pmol) from Example 17, 18 or 26 is dissolved in 425 μl of water, and this solution is heated to 90°C and rapidly cooled. Then 50 μl of 10 x kinase buffer and 50 μl of ^{32}P -gamma-ATP (6,000 Ci/mmol) or ^{35}S -gamma-ATP are added, and the mixture is incubated at 37°C for 1 hour. The reaction is stopped by adding 0.5 M EDTA solution. Desalting takes place with the aid of an NAP^R column from Pharmacia.

Determination of cellular uptake:

Vero cells are incubated in DMEM, 5% FCS, in 96-well microtiter plates at 37°C for 24 hours. After removal of the medium, the cells are washed twice with serum-free DMEM. The radioactively labeled oligomer (10^6 cpm) is diluted with unlabeled oligomer to a concentration of 10 μM in serum, and the cells are incubated at 37°C therewith. 150 μl portions are removed after 1, 7 and 24 hours (called "supernatant 1"). The cells in the wells of the microtiter plates are washed 7 times with 300 μl of fresh medium, and the combined washing media (called "supernatant 2") are measured in a scintillation counter. Then 100 μl of trypsin solution are added, 30 seconds are allowed to elapse, and the supernatant is aspirated off. The cells are detached from the plate by incubating at 37°C for 3 min. The detached cells are transferred into 1.5 ml Eppendorf tubes and centrifuged at 2,000 rpm for 6 minutes ("supernatant 3"). Supernatants 1 (5 μl), 2 and 5 (0.5 ml) are each measured separately in a scintillation counter. From this is calculated the uptake of oligomer in pmol per 100,000 cells, with supernatant 3 representing the cell-bound oligomer fraction and the

- 68 -

total of supernatants 1 and 2 representing the non-cell-bound oligomer fraction.

Results:

5 Incubation time Cellular uptake in pmol
 in hours of oligomer/ 10^5 cells

	PNA/DNA hybrid	DNA
1	0.25	0.36
7	0.54	0.57
24	0.75	0.78

10 Investigation of the stability of the oligomer in medium containing cells:

Supernatant 1 (10 μ l) is mixed with 5 μ l of 80% formamide (with Xylenecyanol and bromphenolblue), heated to 95°C (5 minutes) and loaded onto a polyacrylamide gel (20% acrylamide, 7 M urea). After development of the gel in the electric field, the bands on the gel are assigned by autoradiography to the "stable oligomer", and the missing bands to the "degraded oligomer".

20 The PNA/DNA oligomer from Example 26 is 69% stable after an incubation time of 24 hours; the DNA oligomer is 3% stable.

The PNA/DNA oligomer from Example 31 has a half-life of 32 h under these conditions, whereas the corresponding DNA oligonucleotide has a half-life of about 2 h.

25 Example 42

Determination of cellular uptake by fluorescence labeling:

COS cells are allowed to grow to confluence in Dulbecco's MEM supplemented with 10% FCS in 5 cm Petri dish s. Th
30 cells are washed twice with serum-free DMEM. A steril needle is used to scratch an area of about 1 cm² in th

- 69 -

middle of the Petri dish. The PNA/DNA oligomer solution (0.1 mM) to be investigated is applied to this area. Incubation is carried out at 37°C under a CO₂ atmosphere. The cells are investigated by fluorescence microscopy after 2, 4 and 16 hours. For this, the cells are washed four times with serum-free DMEM, covered with a glass slide and assessed under a fluorescence microscope or by phase contrast. A fluorescence-labeled PNA (without DNA part) F-(but)-tttt ttt-hex was investigated as comparison for the PNA/DNA hybrid molecules. After the cells had been incubated with this PNA for two hours, > 90% of the cells show signs of pronounced morphological changes and cell death. Most of the cells exhibit pronounced vacuolization. The plasma membrane, the cytosol and the nucleus show no uptake of PNA. After incubation with the pure PNA for a further two hours, all the cells have died. The situation is different with the DNA/PNA oligomers according to the invention. After incubation of the cells with the DNA/PNA oligomers for only two hours the cells show punctiform intracellular distribution of the PNA/DNA oligomers. The cells suffer no cell death even after prolonged incubation.

Example 43

Determination of the melting temperatures:

The melting temperatures are determined using an HP 8452A diode array spectrophotometer, an HP 89090A Peltier element and the HP temperature control software Rev.B5.1 (from Hewlett Packard). Measurements are carried out in 0.5°C/min steps in 10 mM HEPES and 140 mM NaCl (pH 7.5) as buffer. The oligomer concentration is 0.5 to 1 OD₂₆₀ per ml.

- 70 -

Result for the product from Example 17 or 18 (T_M with DNA)

	5'-ATC GTC GTA T(Oeg(t))a gtc-hex	$T_M = 51.5^\circ\text{C}$
	3'-TAG CAG CAT A A T CAG-5'	antiparallel
5	5'-ATC GTC GTA T(Oeg(t))a gtc-hex	$T_M < 20^\circ\text{C}$
	5'-TAG CAG CAT A A T CAG-3'	parallel
	5'-ATC GTC GTA TT(but)a gtc-hex	$T_M = 51.0^\circ\text{C}$
	3'-TAG CAG CAT AA T CAG-5'	antiparallel
	5'-ATC GTC GTA TTA GTC-3'	$T_M = 50.5^\circ\text{C}$
10	3'-TAG CAG CAT AAT CAG-5'	DNA-DNA antiparallel
	5'-ATC GTC GTA TT(but)a gtc-hex	$T_M < 20^\circ\text{C}$
	5'-TAG CAG CAT AA T CAG-3'	parallel

Sequence

			T_M with DNA	T_M with RNA (T = U)
15				
	5'-ACA TCA TGG TCG-3'	DNA	ap 50.7°C	48.6°C
	3'-TGT AGT ACC AGC-5'			
	5'-ACA TCA tgg tcg-3'	(PNA/DNA)	ap 54.5°C	54.7°C
	3'-TGT AGT ACC AGC-5'			
20	5'-ACA TCA tgg tcg-3'	(PNA/DNA)	p 20°C	< 20°C
	3'-TGT AGT ACC AGC-3'			
	5'-aca tca tgg tcg-3'	PNA	ap 58.8°C	66.6°C
	3'-TGT AGT ACC AGC-5'			
	5'-aca tca tgg tcg-3'	PNA	p 46.3°C	44.8°C
25	5'-TGT AGT ACC AGC-3'			
	5'-ACA TCA <u>TGG TCG</u> -3'	S-DNA	ap 46.7°C	43.8°C
	3'-TGT AGT ACC AGC-5'			

TGG TCG means a DNA part in which all internucleotide linkages are in phosphorothioate form. See pag 5 for

definition of p and ap.

Example 44

Tests for antiviral activity:

The antiviral activity of the test substances on various
5 human-pathogenic Herpesviruses is investigated in a cell
culture test system. For the experiment, monkey kidney
cells (Vero, $2 \times 10^5/\text{ml}$) are inoculated in serum-contain-
ing Dulbecco's MEM (5% fetal calf serum FCS) in 96-well
10 microtiter plates and incubated at 37°C and 5% CO_2 for
24 h. The serum-containing medium is then aspirated off
and the cells are rinsed twice with serum-free Dulbecco's
MEM (-FCS). The test substances are prediluted in H_2O to
a concentration of $600 \mu\text{M}$ and stored at -18°C . Further
15 dilution steps in Dulbecco's minimal essential medium
(MEM) are carried out for the test. $100 \mu\text{l}$ portions of
the individual test substance dilutions are added to-
gether with $100 \mu\text{l}$ of serum-free Dulbecco's MEM (-FCS) to
the rinsed cells. After incubation at 37°C and 5% CO_2 for
3 h, the cells are infected with Herpes simplex virus
20 type 1 (ATCC VR733, HSV-1 F-strain) or with Herpes
simplex virus type 2 (ATCC VR734, HSV-2 G-strain) in
concentrations at which the cell lawn is completely
destroyed within 3 days. The infection concentration for
HSV-1 is 500 plaque-forming units (PFU) per well, and for
25 HSV-2 it is 350 PFU/well. The test mixtures then contain
test substance in concentrations of $80 \mu\text{M}$ to $0.04 \mu\text{M}$ in
MEM supplemented with 100 U/ml penicillin G and 100 mg/l
streptomycin. All the experiments are carried out as
duplicate determination with the exception of the con-
30 trols which are carried out eight times per plate. The
test mixtures are incubated at 37°C and 5% CO_2 for 17 h.
The cytotoxicity of the test substances is determined
after a total incubation time of 20 h by microscopic
inspection of the cell cultures. The maximum tolerated
35 dose (MTD) is defined as the highest concentration of
product which, under the stated test conditions, does not
yet cause microscopically detectable cell damage.
Subsequently FCS is added to a final concentration of 4%,

- 72 -

and incubation is continued at 37°C and 5% CO₂ for 55 h. The untreated infection controls then show a complete cytopathic effect (CPE). After microscopic inspection of the cell cultures they are then stained with neutral red in accordance with the vital staining method of Finter (1966). The antiviral activity of a test substance is defined as the minimum inhibitory concentration (MIC) which is needed to protect 30-60% of the cells from the cytopathogenic effect caused by the virus. The activity of the PNA/DNA chimeras is in each case better than that of the corresponding DNA oligomers or PNA oligomers.

Example 45

Determination of the in vivo activity: inhibition of c-Fos protein expression in the rat:

The determination takes place as described (Sandkühler et al. (1991) in: Proceedings of the VIth World Congress on Pain, Charlton and Woolf, Editors; Elsevier, Amsterdam; pages 313-318) by superfusion of the spinal cord. After laminectomy of a barbiturate-anesthetized Sprague-Dawley rat, a two-chamber container is formed from silicone to receive the antisense oligomer. One chamber is filled with the antisense PNA/DNA derivative, while the other chamber is filled with the control oligomer (concentration of each 75 µM). The superfusate is exchanged in each case after one hour. After superfusion for 6 hours, c-fos expression is stimulated by heat treatment (52°C) of the rear legs. Inhibition of c-fos expression can be demonstrated immunohistochemically on appropriate tissue section samples. The c-fos antisense oligonucleotide from Example 31 brings about greater inhibition of c-fos expression than does the corresponding DNA oligonucleotide and the corresponding PNA oligomer from Example 33.

Example 46

RNase H assay

To determine the RNase H activity, 1.3 OD of the PNA/DNA oligomer to be investigated are heated with 0.5 OD of the complementary RNA sequence (target sequence) dissolved in 50 μ l of autoclaved water, treated with DEPC (diethyl pyrocarbonate), at 80°C for 5 minutes and subsequently cooled to 37°C within 15 minutes. This results in initial denaturation of both oligomers which, after cooling, form a nucleic acid double strand in sequence-specific manner.

For the assay, this RNA-PNA/DNA duplex is incubated with 10 μ l of RNase H 10 \times buffer, 1 μ l of dithiothreitol (DTT) and 2 μ l (corresponding to 10 u) of RNase H supplied by USB. The incubation mixture is made up with autoclaved, DEPC-treated water to the required total volume of 100 μ l. The samples are incubated at 37°C. For the kinetic investigation, 20 μ l portions of the solution were removed after 0, 2 min, 10 min and 1 h, heated at 95°C for 5 minutes and frozen at -70°C until analyzed. The investigation of the RNase H cleavage of RNA takes place by gel electrophoresis. It emerged that PNA/DNA hybrids which contain deoxyribonucleotide building blocks activate RNase H, with cleavage of the complementary RNA strand whereas the PNA/DNA oligomer emerges undamaged from the reaction. The cleavage reaction with the PNA/DNA oligomer takes place somewhat more slowly than with a corresponding oligodeoxyribonucleotide of equal length and sequence.

Example 47

Preparation of an HeLa cell extract with RNase L activity

An HeLa cell extract was prepared in order to stimulate the activity of cellular endoribonuclease L by the 2',5'-tetraadenylate-PNA/DNA conjugates. For this purpose, 35 bottles were each charged with 20 ml of medium containing Dulbecco's MEM (minimal essential medium) and

- 74 -

10% FCS (fetal calf serum). The cells can be harvested after trypsin treatment. 4 ml of cell harvest are obtained after centrifugation at 1,000 rpm. This is initially made up with 4 ml of water and, after
 5 3 minutes, 4 ml of buffer A (5.48 g of HEPES; 15.5 g of KCl; 2.488 g of Mg acetate; 1,232 μ l of 2-mercaptoethanol and 1 l with water) are added in order to lyse the cells. The solution is then centrifuged at 30,000 rpm (about 100,000 g) in an ultracentrifuge at 0°C for 30 minutes.
 10 The supernatant from 8 ml of cell extract is removed and stored at -20°C for the following investigations.

Example 48

Investigation of activation of RNase L

For investigation of this extract for endonuclease L, initially 0.3 OD of the RNA target sequence is heated
 15 with the particular PNA/DNA oligomers at 80°C for 5 minutes and subsequently cooled to 37°C for the hybridization. The duplex is mixed with 20 μ l of the extract, 1.2 μ l of glycerol and RNase L buffer and
 20 incubated at 37°C. The total volume is then 70 μ l. For the kinetic investigations, samples are removed by pipette at the times of 0, 20 and 60 minutes and heated at 95°C for 5 minutes to denature the enzymes. The samples are lyophilized in a Speedvac and analyzed by gel
 25 electrophoresis. The PNA-2',5'-tetraadenylate conjugates and tetracordycepin analogs activate cellular RNase L, whereas corresponding compounds without the tetraadenylate part do not stimulate RNase L.

Example 49

30 DNA polymerase reaction

The following 81-mer oligodeoxynucleotide is used as template for the DNA polymerase reaction:

5'-GCC CCA GGG AGA AGG CAA CTG GAC CGA AGG CGC TTG TGG AGA AGG AGT
 TCA TAG CTG GGC TCC CTA TAG TGA GTC GTA TTA-3'

- 75 -

The sequence of the PNA/DNA primer is:

H-taa tac gac tca cta (5NH-T)-OH 3'.

A corresponding oligodeoxynucleotide of the sequence

5'-TAA TAC GAC TCA CTA TAG-3' is used as control primer.

5 The primer (0.15 nmol) and the template (0.15 nmol) in
5 μ l of 10 \times PCR buffer (500 m KCl, 100 mM tris-HCl,
pH 9, 1% Triton X-100, 15 mM MgCl₂) are diluted with
35 μ l of water and hybridized by heating to 95°C and
cooling. Then 10 μ l of 2 mM dNTP mixture (nucleoside
10 5'-triphosphates) and 3 μ l of DNA polymerase (Klenow
fragment) are added, and the mixture is incubated at 22°C
and 37°C for 0.5 hour each. The reaction solution is then
analyzed on a 10% polyacrylamide gel (with 1% bis).
pBR322/HaeIII digestion is loaded as marker. The reaction
15 with the control primer shows a double-stranded DNA
fragment with the expected size relative to the marker,
whereas the product from the PNA/DNA primer migrates
somewhat more quickly. In both cases the double strand
migrates considerably faster than the template single
20 strand in the gel electrophoresis.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A polyamide-oligonucleotide derivative of the formula I



5 wherein

q, r, s, t are, independently of one another, zero
or 1, where the total of two or more adjacent
q, r, s and t ≥ 2 ;

x is 1 to 20, 1;

10 DNA is a nucleic acid such as DNA or RNA or a known
derivative thereof;





Li is a covalent linkage between DNA and PNA,
where the covalent linkage comprises a bond or
an organic radical with at least one atom from
the series consisting of C, N, O or S;

15 PNA is a polyamide structure which contains at
least one nucleotide base which is different
from thymine; and

20 F and F' are end groups and/or are linked together
by a covalent bond,
and the physiologically tolerated salts thereof.

2. A polyamide-oligonucleotide derivative as claimed in
claim 1, wherein x is 1 to 5.
3. A polyamide-oligonucleotide derivative as claimed in
25 claim 1, wherein x is 1.
4. A polyamide-oligonucleotide derivative as claimed in
claim 1, wherein
x is 1 and
q = r = 1 and s = t = zero or
30 r = s = 1 and q = t = zero or
q = r = s = 1 and t = zero or
r = s = t = 1 and q = zero.

5. A polyamide-oligonucleotide derivative of the formula Ia and Ib as claim d in claims 1 to 4,



wherein

x is 1 to 20, where

5 when x > 1 r = s = 1 and, at the same time,
q = t = zero and o = n = zero to 5;

- 78 -


q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t ≥ 2 ;

R^2 is hydrogen, hydroxyl, C_1 - C_{18} -alkoxy, halogen, azido or amino;


B is, independently of one another, a base customary in nucleotide chemistry, for example natural bases such as adenine, cytosine, thymine, guanine, uracil, inosine or unnatural bases such as, for example, purine, 2,6-diaminopurine, 7-deazaadenine, 7-deazaguanine, N^4, N^4 -ethanocytosine, N^6, N^6 -ethano-2,6-diaminopurine, pseudoisocytosine, 5-methylcytosine, 5-fluorouracil, 5-(C_3 - C_6)-alkynyluracil, 5-(C_3 - C_6)-alkynylcytosine or the prodrug forms thereof,

and the "curved bracket" indicates that R^2 and the adjacent substituent can be in the 2' position and 3' position or else conversely in the 3' position and 2' position;

Nu is a radical of the formulae IIa or IIb



(IIa)



(IIb)

in which

R^2 and B as defined above;

U is hydroxyl, mercapto, C₁-C₁₈-alkyl, C₁-C₁₈-alkoxy, C₆-C₂₀-aryl, C₆-C₁₄-aryl-C₁-C₈-alkyl, NHR³ or NR³R⁴, and

5 R^3 is C_1 - C_{18} -alkyl or C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, and
 R^4 is C_1 - C_{18} -alkyl or

R³ and R⁴ is, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain another hetero-
atom from the series consisting of O, S, N;

V is oxy, thio or imino;


W is oxo or thioxo;

Y is oxy, thio, methylene or imino;

m is zero to 20;

```
15      0      is zero to 20;
```


D is a radical of the formula III



in which B is as defined above;

D' is a radical of the formula IV

- 80 -



in which B is as defined above;

n is zero to 20;

p is zero to 20;

Li₁, Li₂, Li₃ and Li₄ are each, independently of one


5 another, a structure of the formula V



where, independently of one another,

e is 1 to 5,

V' is oxygen, NH, a bond or a radical of the
10 formula VI



in which

U, V, W and Y are as defined above;

15 G can be C₁-C₁₂-alkanediyl, where alkanediyl can optionally be substituted by halogen, amino, hydroxyl, C₁-C₁₈-alkyl, C₁-C₁₈-alkoxy, C₆-C₁₄-aryl, or C₆-C₁₄-aryl-C₁-C₁₈-alkyl; C₆-C₁₄-aryldi-C₁-C₁₂-alkanediyl, or a group of the formula (CH₂CH₂O)_δCH₂CH₂ in which δ can be 1 to 11; or a bond; and

20 G' is oxy, thio, imino, -C(O)-, -C(O)NH-, a bond or a radical of the formula VI in which U, V, W and Y are as defined above; and

- 81 -

F and F' are linked by a bond and/or

F is $R^0 - (A)_k - V$ - and


F' in formula Ia is $-(Q)^1 - R^1$ and in formula Ib is $V^1 - (A)_1 - R^1$,

5

where

R^0 is hydrogen, C_1 - C_{18} -alkanoyl, C_1 - C_{18} -alkoxy-carbonyl, C_3 - C_8 -cycloalkanoyl, C_7 - C_{15} -aroyl, C_3 - C_{13} -heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or
 10 if k is zero, R^0 is hydrogen or together with V is a radical of the formula VII

15



in which

Z and Z' are, independently of one another, hydroxyl, mercapto, C_1 - C_{22} -alkoxy, C_1 - C_{18} -alkyl, C_6 - C_{20} -aryl, C_6 - C_{14} -aryl- C_1 - C_{18} -alkyl, C_1 - C_{22} -alkylthio, NHR^3 , NR^3R^4 , or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage, and in which

25

R^3 , R^4 , V and W are as defined above;

R^1 is hydrogen or Q^0

30

where R^1 is always only hydrogen when at the same time l is zero and in formula Ia t is zero and s is 1 and Li_1 is a structure of the formula V with $V' = \text{bond}$, $G = \text{bond}$, $e = 1$ and $G' = \text{oxy, thio, imino}$ or a radical of the formula VI with $U = Z$

- 82 -

or

in formula Ib q is 1 or $q = r = \text{zero}$ and
 in $F' = V^1 - (A)_1 - R^1$ with $V^1 = V$,

5 A and Q are, independently of one another, the
 residue of a natural or unnatural amino acid,
 preferably from the series consisting of
 glycine, leucine, histidine, phenylalanine,
 cysteine, lysine, arginine, aspartic acid,
 glutamic acid, proline, tetrahydroisoquinoline-
 10 3-carboxylic acid, octahydroindole-2-carboxylic
 acid, N-(2-aminoethyl)glycine;

Q^0 is hydroxyl, OR' , NH_2 , NHR'' with

$R' = C_1-C_{18}$ -alkyl and

15 $R'' = C_1-C_{18}$ -alkyl, C_1-C_{18} -aminoalkyl, C_1-C_{18} -
 hydroxyalkyl;

V is as defined above;

V^1 is a bond or V, where in F' only in for-
 mula Ib with $q = \text{zero}$ and $r = 1$ V^1 is
 always a bond;

20 k is zero to 10;

l is zero to 10;

with the proviso that

a) if in the compound of the formula Ia t is zero
 and s is 1, and Li_1 is $(V') - (G) - (G')$ with
 25 $V' = \text{a compound of the formula VI}$, $G = C_2-C_{12}$ -
 alkylene and $G' = CO$, in $F' = - (Q)_1 - R^1$ l is
 zero to 10 and R^1 is Q^0 ;

b) if in the compound of the formula Ia
 $s = t = \text{zero}$, Li_2 is a bond;

30 c) if in the compound of the formula Ib t is zero
 and s is 1, Li_3 is a bond;

d) if in the compound of the formula Ib
 $s = t = \text{zero}$, Li_4 is a bond;

35 where each nucleotide can be in its D or L configu-
 ration, and the base can be in the α or β position.

- 83 -

6. A polyamide-oligonucleotide derivative of the formulae Ia and Ib as claimed in claim 5, wherein the base is in the β position.
- 5 7. A process for the preparation of polyamide-oligonucleotide derivatives as claimed in claims 1 to 6, which comprises successive condensation of a PNA unit or DNA unit with, in each case, one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain.
- 10 8. A polyamide-oligonucleotide derivative as claimed in claims 1 to 6 for use as medicine.
- 15 9. A polyamide-oligonucleotide derivative as claimed in claims 1 to 6 for use as medicine for the treatment of diseases caused by viruses or of diseases influenced by integrins or cell-cell adhesion receptors, for the treatment of cancer or for preventing restenosis.
- 10 10. A pharmaceutical containing a polyamide-oligonucleotide derivative as claimed in claims 1 to 6.
- 20 11. A polyamide-oligonucleotide derivative as claimed in claims 1 to 6 for use as gene probe.
- 25 12. A polyamide-oligonucleotide derivative as claimed in claims 1 to 6, wherein a nucleoside unit having a 3'-hydroxyl group is located on at least one end for use as primer.
13. A gene probe assay for the determination of an oligo- or polynucleotide target (RNA or DNA), wherein a gene probe as claimed in claim 11 is used in a homogeneous or heterogeneous assay.

14. A gen probe assay for the determination of an oligo- or polynucleotide target (RNA or DNA), wherein a primer as claimed in claim 12 is used.
15. A gene probe assay as claimed in claims 13 and 14,
5 wherein the target is determined by hybridization after target amplification.